<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786851</article-id><article-id pub-id-type="pii">S2405-8440(25)00361-5</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2025.e41981</article-id><article-id pub-id-type="publisher-id">e41981</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Alpha synuclein and inflammaging</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Putnam</surname><given-names>Genevi&#x000e8;ve L.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Maitta</surname><given-names>Robert W.</given-names></name><email>robert.maitta@case.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff1"><label>a</label>University Hospitals Cleveland Medical Center, Cleveland, OH, USA</aff><aff id="aff2"><label>b</label>Case Western Reserve University School of Medicine, Cleveland, OH, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Andrews 647A, PTH 5077, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. <email>robert.maitta@case.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2025</year></pub-date><volume>11</volume><issue>2</issue><elocation-id>e41981</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by Elsevier Ltd.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>The &#x003b1;-synuclein protein is an established molecule in Lewy body pathology, especially Parkinson's disease (PD). While the pathological role of &#x003b1;-synuclein (&#x003b1;-syn) in PD has been well described, novel evidence may suggest that &#x003b1;-syn interacts with inflammasomes in response to aging. As age is an inevitable physiological state and is also considered the greatest risk factor for PD, this calls for investigation into how &#x003b1;-syn, aging, and PD could be linked. There is a growing amount of data regarding &#x003b1;-syn normal function in the body that includes involvement in cellular transport such as protein complexes assembly, vesicular trafficking, neurotransmitter release, as well as immune cell maturation. Regarding abnormal &#x003b1;-syn, a number of autosomal dominant mutations have been identified as causes of familial PD, however, symptomatology may not become apparent until later in life due to compensatory mechanisms in the dopaminergic response. This potentially links age-related physiological changes not only as a risk factor for PD, but for the concept of &#x0201c;inflammaging &#x0201d;. This is defined as chronic inflammation that accompanies aging observed in many neurodegenerative pathologies, that include &#x003b1;-syn's ability to form oligomers and toxic fibrils seen in PD. This oligomeric &#x003b1;-syn stimulates pro-inflammatory signals, which may worsen PD symptoms and propagate chronic inflammation. Thus, this review will explore a potential link between &#x003b1;-syn's role in the immune system, inflammaging, and PD.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Alpha Synuclein has physiological roles important to organ systems outside the central nervous system.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Alpha Synuclein interacts with elements mediating inflammatory processes.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Alpha Synuclein may be important to inflammageing and changes associated with aging.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Alpha Synuclein's role in immunity is indicative of the importance of this protein.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>&#x003b1;-synuclein</kwd><kwd>Aging</kwd><kwd>Inflammaging</kwd><kwd>Inflammation</kwd><kwd>Parkinson's disease</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Parkinson's disease (PD), a devastating and incurable illness, was first identified in 1817 by Dr. James Parkinson, who used the term &#x0201c;shaking palsy&#x0201d; to describe the syndrome's symptomatology [<xref rid="bib1" ref-type="bibr">1</xref>]. This disease is a devastating neurodegenerative disorder affecting approximately 500,000 Americans with complications such as dystonia, impaired cognitive function, and dyskinesia [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>]. Worldwide the disease affects as many as 6.1&#x02013;8.5 million people with a lifetime incidence of approximately 2&#x000a0;%, thus representing one of the most debilitating neurological diseases [<xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>]. Caused by the incremental loss of dopaminergic neurons in the substantia nigra, one of the primary suspects mediating PD pathology is &#x003b1;-synuclein (&#x003b1;-syn), a protein identified in 1994, whose sequence was found to be highly homologous to synucleins first described in the torpedo ray [<xref rid="bib7" ref-type="bibr">7</xref>].</p><p id="p0035">&#x003b1;-syn is a relatively small 140 amino acid long protein that is a major component of Lewy bodies (LB) found in PD [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. It belongs to a protein family which also has two other members, &#x003b2;- and &#x003b3;-syn, whose functions remain mostly to be determined [<xref rid="bib9" ref-type="bibr">9</xref>]. Each synuclein has defined tissue distribution and apparently specific functions in the body, but &#x003b1;-syn is mostly found in the brain and ubiquitously minimally expressed in heart, lung, kidney and skeletal muscle [<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. The synuclein family shares a highly conserved sequence in vertebrates capable of oligomerization responsible for pathology [<xref rid="bib12" ref-type="bibr">12</xref>], that for &#x003b1;-syn defines a disease group known as synucleinopathies [<xref rid="bib13" ref-type="bibr">13</xref>]. &#x003b1;-syn is an intrinsically disordered and soluble protein monomer that can fold into a fibrillar conformation that promotes aggregation when mutated [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>]. It is encoded by the <italic>SNCA</italic> gene, and mutations and multiplications of this gene are linked to familial forms of PD.</p><p id="p0040">While the &#x003b1;-syn protein has been predominantly studied in neural tissues, it has also been found to exist in megakaryocytes and especially in platelets in high concentrations [<xref rid="bib16" ref-type="bibr">16</xref>,<xref rid="bib17" ref-type="bibr">17</xref>]. Interestingly, this protein has been shown to be essential for the maturation of lymphocytes and for normal hematopoiesis to occur [<xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>, <xref rid="bib21" ref-type="bibr">[21]</xref>]. When &#x003b1;-syn is absent, marked disorders in lymphoid organ morphology, development and function of leukocytes, signs of anemia, platelet dysfunction, and lymphoid defects that include absent IgG production, cytokine dysregulation, and accumulation of intracellular inclusions among others are observed [<xref rid="bib21" ref-type="bibr">21</xref>]. How &#x003b1;-syn mediates what appear to be multiple levels of function in normal hematopoiesis and lymphopoiesis remains to be elucidated. However, the domains of the protein that mediate these multiple functions in hematopoietic cells may be the same as observed in the central nervous system (CNS) [<xref rid="bib22" ref-type="bibr">22</xref>].</p><p id="p0045">&#x003b1;-syn is capable of bidirectional movement between the gut and the brain, and even though it is not known if this movement is part of its normal physiologic role or if this contributes to pathology, age may play a role in this mechanism [<xref rid="bib23" ref-type="bibr">23</xref>]. Nevertheless, despite age being recognized as a risk factor in PD development, it is clear that age-related changes do not lead to every individual developing the disease. Humans accumulate age-related cellular damage; among them a systemic-long-term inflammation process described as &#x0201c;inflammaging&#x0201d; that may constitute the &#x0201c;first hit&#x0201d; in a series of events leading to development of age-related diseases [<xref rid="bib24" ref-type="bibr">24</xref>]. Whereas a low-grade, chronic inflammatory state occurring in the CNS secondary to long-standing exposure to inflammatory stimuli, defines the hallmarks of the process known as &#x0201c;neuroinflammaging&#x0201d; which predisposes an individual to either cerebrovascular or neurodegenerative disorders [<xref rid="bib25" ref-type="bibr">25</xref>]. Thus, an important area of interest is how inflammaging in peripheral systems could lead to cerebral PD pathology in select human populations. In this review, we will explore the basis by which &#x003b1;-syn may interact with inflammaging processes needed to be addressed in future experimentation, prevention, and treatment. To gather literature for this narrative review, PubMed was searched for articles using combinations of the following: &#x003b1;-synuclein, PD, inflammaging, neuroinflammaging, age, aging as search criteria.</p></sec><sec id="sec2"><label>2</label><title>Structure and function of &#x003b1;-synuclein</title><sec id="sec2.1"><label>2.1</label><title>Wildtype and mutant structures</title><p id="p0050">The structure of &#x003b1;-syn spans three distinct domains. The first is the N-terminus, which is a positively charged, highly repetitive, conserved and amphipathic domain closely associated to or bound to lipid membranes (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) [<xref rid="bib26" ref-type="bibr">26</xref>]. In wild type (WT) &#x003b1;-syn, the first series of amino acids in this region prevent aggregation and induce &#x003b1;-helical formation at lipid membranes [<xref rid="bib27" ref-type="bibr">27</xref>]. The core central hydrophobic (NAC) region is capable of forming fibrils and &#x003b2;-sheets. Lastly, the C-terminus is acidic, highly hydrophilic, and can take on the form of coils. Aggregation is also possible in this region if the random coil structure is electrostatically disrupted or if the serine 129 residue is dephosphorylated [<xref rid="bib28" ref-type="bibr">28</xref>].<fig id="fig1"><label>Fig. 1</label><caption><p>Representation of monomeric &#x003b1;-synuclein structure with most common point mutations in relation to the N-terminal domain. For reference serine residue 129 which undergoes phosphorylation in the C-terminal domain is shown. This figure is adapted from Refs. [<xref rid="bib165" ref-type="bibr">165</xref>,<xref rid="bib166" ref-type="bibr">166</xref>]. Graph shows the three known regions of &#x003b1;-syn. Amino terminus binds membrane structures, central domain is mostly freely accessible and carboxy terminus interacts with protein complexes.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0055">The first mutation identified was a G209A substitution corresponding to the A53T mutation. This mutation was found to be inherited in an autosomal dominant manner and was deemed responsible for early-onset PD [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib29" ref-type="bibr">29</xref>]. Since then, other mutations identified were found to be associated with the familial form of the disease. On the other hand, sporadic cases account for the majority of PD patients. Of note, for the sporadic version of PD, the A18T and A29S mutations occur upstream of those that are familial [<xref rid="bib30" ref-type="bibr">30</xref>]. Each of these mutations occurs in the amphipathic repeat region of the SNCA gene and can thus impact lipid interaction [<xref rid="bib14" ref-type="bibr">14</xref>]. The protein forms two amphipathic helices that penetrate the lipid bilayer which becomes defective in the setting of mutations away from the N-terminal helix toward helix 2 possibly representing a step toward disease progression [<xref rid="bib31" ref-type="bibr">31</xref>]. Nevertheless, the net effect of these point mutations is changes to lipid-induced fibril production that lead to pathology [<xref rid="bib32" ref-type="bibr">32</xref>]. Since &#x003b1;-syn is the major component of Lewy bodies, mutations lead to changes in the rate of formation of these structures.</p><p id="p0060">To date, a number of major <italic>SNCA</italic> point mutations have been described and have been linked to the familial form of the disease, including V15A, A30P, E46K, H50Q, G51D, A53V and A53T [<xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>, <xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>]. These mutations lead to distinct and at times dramatic phenotypes that for A53T, E46K, and H50Q result in promotion of higher rates of &#x003b1;-syn aggregation, A30P causes slower fibrillary formation, while G51D promotes cellular toxicity in the setting of reduced aggregation [<xref rid="bib38" ref-type="bibr">38</xref>,<xref rid="bib39" ref-type="bibr">39</xref>]. A53V mutations have strong family penetrance with more significant symptoms in families of a particular geographic region [<xref rid="bib40" ref-type="bibr">40</xref>]. Experiments have shown that rapid formation of &#x003b1;-syn amyloid aggregates are seen with A30P, E46K, H50Q and A53T in liquid-liquid phase separation while A53E was characterized by reduced rate of aggregation [<xref rid="bib41" ref-type="bibr">41</xref>]. G51D leads to earlier disease onset hinting to a distinct pathologic mechanism brought about by this mutation [<xref rid="bib39" ref-type="bibr">39</xref>]. Since &#x003b1;-syn oligomers appear to be the neurotoxic form that causes cell death, mutations that facilitate their formation are likely more toxic [<xref rid="bib42" ref-type="bibr">42</xref>]. However, even though the same mutation can be found in different individuals, there is great heterogeneity in the phenotype caused by them, as shown by E46K mutation which can range from limited aggressive disease to one that is more pronounced [<xref rid="bib43" ref-type="bibr">43</xref>].</p><p id="p0065">Based on aggregation results of &#x003b1;-syn mutations, nucleation-polymerization and nucleation-conversion polymerization processes can be reconciled into one continuous hypothesis [<xref rid="bib44" ref-type="bibr">44</xref>]. In such hypothesis, A30P, E46K and A53T lead to polymorphic &#x003b1;-syn fibril formation in which the latter greatly enhances fibrils elongation in the presence of increasing &#x003b1;-syn seeding, thus explaining how this mutation results in early onset of familial PD [<xref rid="bib44" ref-type="bibr">44</xref>]. This is partly due to A53T markedly enhancing &#x003b1;-syn nucleation rate through the conversion of monomers to amyloid nuclei and fibril elongation (similar to C-terminal truncation) [<xref rid="bib45" ref-type="bibr">45</xref>]. Conversely, A30P can mediate faster oligomers formation with delayed conversion of these into fibrils [<xref rid="bib46" ref-type="bibr">46</xref>]. For G51D, fibrils formed leads to a highly toxic form of &#x003b1;-syn [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. On the other hand, E46K elicits a more pathogenic and stable fibril structure [<xref rid="bib49" ref-type="bibr">49</xref>]. Mechanistically, A30P and A53T may also result in early disease onset as shown by patients expressing these mutations being devoid of brain vesicle-binding in the pre-synaptic region that profoundly disrupts neurotransmitter release [<xref rid="bib50" ref-type="bibr">50</xref>]. Experimentally, neurons expressing A30P or A53T have reduced axonal transport [<xref rid="bib51" ref-type="bibr">51</xref>]. Of interest, in animal models A30P, H50Q and G51D mutations result in reduced phosphorylation of serine 129&#x000a0;at the C-terminus, A53T leads to little change in phosphorylation, while E46K results in much higher phosphorylation [<xref rid="bib52" ref-type="bibr">52</xref>]. However, it the presence of E46K mutation, phosphorylation of serine 129 may be rendered irreversible [<xref rid="bib52" ref-type="bibr">52</xref>].</p><p id="p0070">Recently, a new mutation (A30G) in a family of mediterranean origin, that leads to intrinsically disordered protein aggregates with reduced membrane binding and readily able to form fibrils was reported [<xref rid="bib53" ref-type="bibr">53</xref>]. This mutation leads to a rapid conformational change with reduced helical structure in the portion of the protein embedded in the membrane bilayer resulting in inefficient anchoring and thus impaired vesicle docking at the synapse [<xref rid="bib54" ref-type="bibr">54</xref>]. Separately, another &#x003b1;-syn mutation, A53E, results in a type of multiple system atrophy with Parkinson's-like phenotype suggesting that a mutation automatically does not quality as the cause of PD [<xref rid="bib55" ref-type="bibr">55</xref>]. Taken together, all of these reports likely show that there is no unified mechanism mediated by &#x003b1;-syn mutations since each appears to affect function in specific ways.</p><p id="p0075">Under homeostatic/physiologic conditions, &#x003b1;-syn takes on the form of a disordered monomer or helical tetramer that can perform neuroprotective inhibition of p53 (which can mediate cell cycle arrest, DNA repair, and apoptosis) and caspase-3 [<xref rid="bib56" ref-type="bibr">56</xref>]. It has also been found to regulate synaptic vesicle release and trafficking [<xref rid="bib57" ref-type="bibr">57</xref>]. When mutated, &#x003b1;-syn amyloid fibrils work as infectious agents and propagate in a prion-like manner that cause the formation and deposition of neurotoxic LB [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib57" ref-type="bibr">57</xref>]. Nevertheless, even though the above-mentioned mutations have been being identified as potential causes of familial PD, gene multiplication, truncation, or overproduction are linked to sporadic cases, and the specific pathogenic structure in these instances remain unknown [<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib58" ref-type="bibr">58</xref>,<xref rid="bib59" ref-type="bibr">59</xref>]. Interestingly, patients with sporadic disease may have greater amounts of &#x003b1;-syn in blood compared to those with familial (A53T) mutations suggesting that distinct deregulation of the protein's homeostasis occurs in sporadic vs. familial forms of the disease [<xref rid="bib60" ref-type="bibr">60</xref>]. Furthermore, unlike the former, patients with this mutation can present with retinal changes that may represent a prodromal manifestation of disease [<xref rid="bib61" ref-type="bibr">61</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>Compensatory mechanisms in PD</title><p id="p0080">PD is characterized by both motor and non-motor symptomatology. While motor functional changes do not become apparent until a greater depletion in dopamine occurs (&#x0003e;80&#x000a0;%) [<xref rid="bib62" ref-type="bibr">62</xref>], some non-motor signs can manifest years earlier due to the chronic degeneration of dopaminergic neurons [<xref rid="bib63" ref-type="bibr">63</xref>]. However, neuronal loss alone fails to explain interindividual differences in motor phenotypes and rates of functional decline [<xref rid="bib64" ref-type="bibr">64</xref>]. This implies that alternate phenomena such as neuroplasticity in which nigral neuronal efficacy, changes in neurotransmitter conduction, expression of molecular mediators, and even increase in physical activity compensate for loss of dopamine and these play a major role during the earlier years of disease [<xref rid="bib65" ref-type="bibr">65</xref>]. Favoring this view, neuroimaging patient data has shown that primary motor cortex-striatal networks, and specifically intercortical connections, become more efficient with progressive loss of dopaminergic terminals in the putamen suggesting that cortical plasticity in PD occurs [<xref rid="bib66" ref-type="bibr">66</xref>]. Also, mutations in the glucocerebrosidase gene are characterized by early onset of symptoms, a more pronounced cognitive decline, and reduced levels of &#x003b1;-syn in cerebrospinal fluid [<xref rid="bib67" ref-type="bibr">67</xref>], implying that this may constitute a compensatory mechanism. Animal data has also directly linked &#x003b1;-syn overexpression to mild losses of dopaminergic neurons and dopamine neurotransmitter levels in the substantia nigra, as well as residual dopaminergic neurons displaying smaller cell bodies, reduced dendritic branching and hyperexcitability [<xref rid="bib68" ref-type="bibr">68</xref>]. Thus, taking abnormal &#x003b1;-syn propagation as a determinant of disease, data indicating improved parieto-premotor activity in patients with a milder motor phenotype favors a compensatory phenotype [<xref rid="bib64" ref-type="bibr">64</xref>]. This indicates that nigral dopaminergic neurons are able to adapt during PD neurodegeneration. As a result, this level of neural adaptation represents an opportunity to develop new therapeutic agents to treat symptomatology.</p></sec><sec id="sec2.3"><label>2.3</label><title>Connections to PD</title><p id="p0085">As mentioned earlier, the general consensus is that &#x003b1;-syn can act in a prion-like fashion and that elevated levels of aggregates or fragmentation of the protein accelerate LB formation [<xref rid="bib59" ref-type="bibr">59</xref>,<xref rid="bib69" ref-type="bibr">69</xref>]. Experimental data has shown that when mice are injected with only a single dose of &#x003b1;-syn fibrils, they develop LB capable of propagating throughout different cell types in neighboring brain regions [<xref rid="bib70" ref-type="bibr">70</xref>]. Specifically, aggregation occurs in a sigmoidal fashion, where the initial lag phase accelerates into a growth phase as monomers preferentially build onto existing aggregates rather than other monomers. This aggregation can then promote formation of beta-sheet-rich amyloid fibrils that are capable of forming LB [<xref rid="bib57" ref-type="bibr">57</xref>,<xref rid="bib71" ref-type="bibr">71</xref>]. This is further supported by observations that when mutated, the &#x0201c;critical&#x0201d; N-terminal domain allows for enhanced binding while promoting oligomerization and LB formation [<xref rid="bib56" ref-type="bibr">56</xref>]. Further studies have also found that truncated C-terminal domains can increase &#x003b1;-syn fibrillation [<xref rid="bib72" ref-type="bibr">72</xref>,<xref rid="bib73" ref-type="bibr">73</xref>]. The net result of aggregation is the inhibition of dopaminergic neurons leading to PD motor deficits [<xref rid="bib74" ref-type="bibr">74</xref>,<xref rid="bib75" ref-type="bibr">75</xref>]. Along these lines, overexpression of &#x003b1;-syn in an in vitro model has been reported to cause extensive dopaminergic neuronal loss after just three months [<xref rid="bib75" ref-type="bibr">75</xref>]. This was further supported by studies showing that overexpression of WT &#x003b1;-syn in vivo and in vitro was detrimental to dopamine neurotransmitter transport due to the reduced concentration (40&#x000a0;%) of vesicles containing dopamine at synapses [<xref rid="bib76" ref-type="bibr">76</xref>,<xref rid="bib77" ref-type="bibr">77</xref>]. Accumulation of &#x003b1;-syn also leads to activation of the unfolded-protein response pathway in the endoplasmic reticulum (ER) in patients with PD [<xref rid="bib78" ref-type="bibr">78</xref>], which when in high levels may create a more significant chronic ER stress accentuating neurodegeneration (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) [<xref rid="bib79" ref-type="bibr">79</xref>]. It is important to note that in sporadic cases of PD, &#x003b1;-syn levels are not overall increased but instead its phosphorylation or proportion of insoluble &#x003b1;-syn increases [<xref rid="bib80" ref-type="bibr">80</xref>].<fig id="fig2"><label>Fig. 2</label><caption><p>Diagram of &#x003b1;-syn interactions with inflammasome and inflammatory pathways in the cell. This includes activation of TLR-mediated pathways, gene expression, NLRP3 and the inflammasome, ROS and increase in inflammatory cytokines, activation of the unfolded protein response (UPR) and chronic endoplasmic reticulum (ER) stress (ERS) pathway, with feedback and communication among pathways that can be self-amplified with additional &#x003b1;-syn aggregation.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.4"><label>2.4</label><title>Global involvement of &#x003b1;-syn in the immune system</title><p id="p0090">Although the role of &#x003b1;-syn in aggregate formation is important, this protein has also been linked to the activation of the innate immune response and maturation of the adaptive immune system [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib81" ref-type="bibr">81</xref>,<xref rid="bib82" ref-type="bibr">82</xref>]. Microglia, the myeloid-derived innate immune cells of the CNS, are responsible for phagocytosing infectious agents or native tissue debris caused by injury or cell death [<xref rid="bib80" ref-type="bibr">80</xref>,<xref rid="bib83" ref-type="bibr">83</xref>]. Once activated in this way, microglia undergo morphological changes, secrete cytokines or recognize CD4<sup>+</sup> cells via major histocompatibility complex (MHC)-II antigen presentation [<xref rid="bib80" ref-type="bibr">80</xref>,<xref rid="bib84" ref-type="bibr">84</xref>]. However, there is still debate surrounding how microglia interact temporally with &#x003b1;-syn, since results have varied markedly depending upon the brain areas examined by a given study and the type of &#x003b1;-syn used in experiments [<xref rid="bib85" ref-type="bibr">85</xref>]. For example, upregulation of MHC-II expression as well as genes for proinflammatory cytokines on microglia of PD patients has been reported [<xref rid="bib86" ref-type="bibr">86</xref>]. Furthermore, this increase in microglial MHC-II expression has been observed in tandem with &#x003b1;-syn inclusions prior to neurodegeneration, suggesting that the initial buildup of &#x003b1;-syn caused the increase in MHC-II on microglia [<xref rid="bib80" ref-type="bibr">80</xref>]. While this may not be the sole cause of neurodegeneration, the results allowed for a possible link between neuroinflammation followed by neurodegeneration to be formed [<xref rid="bib80" ref-type="bibr">80</xref>]. Notably, microglia activation appears to occur prior to the accumulation of &#x003b1;-syn but the mechanism mediating this remains to be elucidated [<xref rid="bib84" ref-type="bibr">84</xref>]. Nevertheless, even though these results were different from what was seen in microglia of the substantia nigra, the increase in cytokines after microglial activation was similar to previous studies supporting the conclusion that cytokines can drive dopaminergic neuronal dysfunction in PD patients [<xref rid="bib84" ref-type="bibr">84</xref>,<xref rid="bib87" ref-type="bibr">87</xref>]. Thus, it is apparent that &#x003b1;-syn accumulation is associated with increased MHC-II expression in immune cells [<xref rid="bib88" ref-type="bibr">88</xref>].</p><p id="p0095">It has been further proposed that &#x003b1;-syn aggregation may encourage phagocytic exhaustion, which can also lead to the degradation of dopaminergic neurons [<xref rid="bib89" ref-type="bibr">89</xref>]. Regarding WT &#x003b1;-syn, microglia become activated during its release and promote autophagy to remove monomers via toll-like receptor 4 (TLR4) and the NF-&#x003ba;B-p62 inflammatory pathways before degeneration can occur (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) [<xref rid="bib90" ref-type="bibr">90</xref>,<xref rid="bib91" ref-type="bibr">91</xref>]. In a similar manner, &#x003b1;-syn also interacts with TLR2 amplifying immune activation and chronic inflammation [<xref rid="bib91" ref-type="bibr">91</xref>]. Importantly, many more proteins participate in this process, and thus mutations can lead to inappropriate autophagy (<xref rid="fig2" ref-type="fig">Fig. 2</xref>) [<xref rid="bib92" ref-type="bibr">92</xref>,<xref rid="bib93" ref-type="bibr">93</xref>]. Specifically, &#x003b1;-syn can activate TLR2 and TLR4 in a concentration-dependent manner and prevent proper microglial autophagy while regulating inflammation, thus contributing to neuroinflammation and PD pathology. It can also activate heterodimers of TLR2/TLR1 and TLR2/TLR6 resulting in increased production of tumor necrosis factor and interleukin (IL)-1&#x003b2; [<xref rid="bib94" ref-type="bibr">94</xref>]. While this lends support to &#x003b1;-syn association with increases in p62 transcription (an autophagy receptor) that suggest suppression of autophagy, findings also support that &#x003b1;-syn could promote a non-transcriptional increase in p62 and prevent autophagy from taking place even when <italic>de novo</italic> synthesis is blocked [<xref rid="bib90" ref-type="bibr">90</xref>,<xref rid="bib95" ref-type="bibr">95</xref>].</p><p id="p0100">MHC-II and &#x003b1;-syn are important to the adaptive immune response, since the former is responsible for antigen presentation to lymphocytes, especially T cells [<xref rid="bib95" ref-type="bibr">95</xref>]. In &#x003b1;-syn-knockout (KO) mice, it was found that animals had markedly defective T cell maturation, as indicated by increases in CD4<sup>&#x02212;</sup>CD8<sup>&#x02212;</sup> precursors and low mature CD4<sup>+</sup> and CD8<sup>+</sup> single positive T cells [<xref rid="bib18" ref-type="bibr">18</xref>]. Importantly, remaining single positive CD4<sup>+</sup> and CD8<sup>+</sup> T cells were hyperactive as indicated by higher expression of early activation markers, increased IL-2 production and impaired Th2 differentiation [<xref rid="bib18" ref-type="bibr">18</xref>]. Along these lines, absence of &#x003b1;-syn led to morphological changes in leukocytes indicative of intracellular transport deficits as indicated by accumulation of vacuoles and vesicles in cells [<xref rid="bib20" ref-type="bibr">20</xref>]. This implies that &#x003b1;-syn aggregation can impact the homing abilities of helper T cells and microglial phagocytic functions [<xref rid="bib81" ref-type="bibr">81</xref>,<xref rid="bib96" ref-type="bibr">96</xref>,<xref rid="bib97" ref-type="bibr">97</xref>]. These T cell deficits were accompanied by upregulation of IFN-&#x003b3;, indicating enhanced pro-inflammatory activity of these cells capable of activating microglia [<xref rid="bib81" ref-type="bibr">81</xref>]. Lastly, dopaminergic neurons in the substantia nigra expressed MHC-I when activated by cytokines released by microglia after &#x003b1;-syn exposure, and this MHC-I expression becomes a target for CD8<sup>+</sup> T cells [<xref rid="bib98" ref-type="bibr">98</xref>].</p></sec></sec><sec id="sec3"><label>3</label><title>&#x003b1;-syn and SNAREs</title><sec id="sec3.1"><label>3.1</label><title>SNARE structure and function</title><p id="p0105">For neurological signaling to take place, neurotransmitters must be released via vesicular transport and travel across the synaptic cleft from a presynaptic neuron to bind to receptors on the corresponding postsynaptic neuron. Fusion of these synaptic vesicles to release neurotransmitters is dependent upon soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) complexes. SNAREs are highly conserved proteins and membrane fusion events include some of the better-known SNAREs including synaptobrevin2 (Syp2) [also known as vesicle-associated membrane protein 2 (VAMP2)], syntaxin-1 (Stx-1), and 25-kD synaptosome-associated protein (SNAP-25) [<xref rid="bib99" ref-type="bibr">99</xref>]. However, it is important to note that there are 35 other known SNARE proteins and their use varies based on the type of synapse. SNAREs were originally divided into two broad groups: v-SNAREs (vesicle) and t-SNAREs (target), however, they may also be classified as r-SNARES (typically vesicular), or q-SNARES (usually on target membranes) since the t/v categorization could not account for alternative structures or homotypic events [<xref rid="bib21" ref-type="bibr">21</xref>]. The SNARE proteins assemble into a highly stable coiled-coil tetramer called a synaptic fusion trans-complex to link the membranes of synaptic vesicles and presynaptic neurons for neurotransmitter release [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib100" ref-type="bibr">100</xref>]. Typically, this requires one Stx-1, one VAMP2, and two SNAP-25 proteins. These trans-complexes transition to a cis-formation during fusion, which allows for dissociation due to ATPase activity via the recruitment of SNAP-25 and thus permitting SNARE proteins to be recycled for future synaptic fusion events [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>, <xref rid="bib103" ref-type="bibr">[103]</xref>, <xref rid="bib104" ref-type="bibr">[104]</xref>].</p></sec><sec id="sec3.2"><label>3.2</label><title>SNAREs and immunological synapse</title><p id="p0110">There is general agreement based on in vivo and in vitro studies that &#x003b1;-syn promotes SNARE docking and complex assembly in presynaptic neurons via the cross-linking of its C-terminal region with the N-terminal domain of VAMP2 [<xref rid="bib105" ref-type="bibr">[105]</xref>, <xref rid="bib106" ref-type="bibr">[106]</xref>, <xref rid="bib107" ref-type="bibr">[107]</xref>]. Experiments have shown that using high levels of exogenous &#x003b1;-syn inhibits vesicular fusion to the synaptic membrane, which confirms that the protein regulates SNARE function [<xref rid="bib108" ref-type="bibr">108</xref>,<xref rid="bib109" ref-type="bibr">109</xref>]. SNAREs also play a key role in the transport of cell signaling molecules, which are vital for &#x003b1;-syn to carry out its interactions with the immune system. This is especially the case for phagocytic cells such as microglia and mechanisms mediating autophagy. Data indicates that when microbial invasion occurs, Stx11 and SNAP-23 (the latter of which is located in macrophages) work together to transport TLR4 to allow for secretion of pro-inflammatory factors [<xref rid="bib110" ref-type="bibr">110</xref>,<xref rid="bib111" ref-type="bibr">111</xref>]. Stx11 has also been reported to be upregulated on monocytes and compete with other SNAREs to downregulate clearance of apoptotic cells by macrophages [<xref rid="bib112" ref-type="bibr">112</xref>]. Likewise, SNAP-23 has been found to mediate maturation of phagosomes and FcR-mediated phagocytosis in macrophages [<xref rid="bib113" ref-type="bibr">113</xref>]. Similarly, Stx17 localizes to autophagosomes for targeting the endosomes/lysosomes for degradation [<xref rid="bib114" ref-type="bibr">114</xref>]. Cumulatively, this data indicates that SNARE complexes are essential for normal immune responses to be carried out throughout the body.</p><p id="p0115">In addition to the role of SNAREs in the innate immune system, they have also been shown to influence T cell infiltration. MHCs on antigen-presenting cells present antigens to T cell receptors (TCRs) resulting in T cell activation [<xref rid="bib115" ref-type="bibr">115</xref>]. This immunological synapse between the two cell populations is a hub for vesicle trafficking that drives the secretion of cytokines and other signaling molecules as part of the adaptive immune response [<xref rid="bib116" ref-type="bibr">116</xref>]. Regarding SNARE involvement, results have shown that after TCR activation, a membrane-bound molecule called the linker for activation of T cells is transported to the Golgi in a retrograde manner by Stx16, while VAMP7 assists this linker's anterograde transport to the immunological synapse [<xref rid="bib117" ref-type="bibr">117</xref>]. An additional pathway post-TCR activation involves VAMP8 and Stx11 interaction with SNAP-23 and Stx4 to exocytose recycling endosomes. This is of importance in T cell cytotoxic activity via granular release that is mediated by Stx11/SNAP-23 complexes [<xref rid="bib118" ref-type="bibr">118</xref>,<xref rid="bib119" ref-type="bibr">119</xref>]. Syp2 is also implicated in granule-specific release in a way similar to that in neuronal axons [<xref rid="bib120" ref-type="bibr">120</xref>]. Additional SNARE proteins known to be involved in T cell cytotoxicity include Stx8 for lytic granule trafficking while SNAP-23, Stx3, and Stx4 mediate chemokine release [<xref rid="bib121" ref-type="bibr">121</xref>,<xref rid="bib122" ref-type="bibr">122</xref>].</p></sec><sec id="sec3.3"><label>3.3</label><title>SNARE interaction with &#x003b1;-syn under homeostatic conditions</title><p id="p0120">It should be evident that even though &#x003b1;-syn has been shown not only to interact but influence SNARE complex assembly, the exact physiological underpinnings of this interaction remain to be defined [<xref rid="bib123" ref-type="bibr">123</xref>]. In vitro findings have shown that inhibition of SNARE complex formation is dependent upon the concentration of &#x003b1;-syn and its interaction with the membrane bilayer (not the complex directly), so long as there are accessible lipids [<xref rid="bib108" ref-type="bibr">108</xref>]. In particular, high concentrations of monomeric &#x003b1;-syn inhibits vesicle docking via the binding of acidic lipids, but does not come into contact with VAMP2 [<xref rid="bib82" ref-type="bibr">82</xref>]. Arachidonic acid stimulates SNARE complex assembly; however, experimental data indicates that &#x003b1;-syn sequesters arachidonic acid and thus prevents SNARE activation for fatty acid exocytosis regardless of acid concentration [<xref rid="bib124" ref-type="bibr">124</xref>]. Notably, this is not the case in the absence of arachidonic acid regardless of &#x003b1;-syn concentration, suggesting that arachidonic acid acts as a modulator of SNARE complexes while &#x003b1;-syn exerts its effect on SNARE complexes without direct interaction with SNARE proteins [<xref rid="bib124" ref-type="bibr">124</xref>].</p><p id="p0125">Conversely, other studies have suggested that &#x003b1;-syn promotes SNARE docking and therefore complex assembly via the cross-linking of its C-terminal region with the N-terminal domain of VAMP2 [<xref rid="bib105" ref-type="bibr">105</xref>]. This can occur in a nonclassical chaperone mechanism in which &#x003b1;-syn directly supports SNARE complex formation through a binding pattern similar to that seen in neurons [<xref rid="bib123" ref-type="bibr">123</xref>]. Still, others have suggested that this occurs via &#x003b1;-syn clustering of vesicles in active zones to increase complex assembly kinetics that are dependent on the presence of anionic lipids [<xref rid="bib125" ref-type="bibr">125</xref>]. SNAREs themselves have also been shown to control &#x003b1;-syn release in a calcium-dependent manner that is regulated by the autophagy-lysosomal pathway [<xref rid="bib126" ref-type="bibr">126</xref>]. The t-SNAREs involved in this process were Stx4, SNAP-23, and VAMP3/7/8 all of which played a role in &#x003b1;-syn exocytosis, although VAMP8 played the largest role [<xref rid="bib126" ref-type="bibr">126</xref>].</p></sec><sec id="sec3.4"><label>3.4</label><title>SNARE interaction with &#x003b1;-syn mutants</title><p id="p0130">Analysis of the transcriptomes of PD patients indicated that the main effect of mutations was over exocytosis and SNARE interaction, including VAMP2 and Stx1 [<xref rid="bib127" ref-type="bibr">127</xref>]. When VAMP2 interacts with oligomers of &#x003b1;-syn, it can no longer bind to t-SNAREs, preventing exocytosis [<xref rid="bib127" ref-type="bibr">127</xref>]. Of the known mutations identified as both familial and capable of inhibiting fusion, E46K did so more than WT &#x003b1;-syn, A30P was less capable, while A53T was shown to have equal inhibitory effects as WT [<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib82" ref-type="bibr">82</xref>,<xref rid="bib108" ref-type="bibr">108</xref>]. A53T has also been linked to lower ER/Golgi SNARE assembly in vitro that can be rescued by overexpression of SNAREs to replace those that are inactivated [<xref rid="bib128" ref-type="bibr">128</xref>,<xref rid="bib129" ref-type="bibr">129</xref>]. Of note, if phosphatidylserine is removed from t-SNARE vesicles &#x003b1;-syn can prevent docking, and if the &#x003b1;-syn C-terminus that binds VAMP2 is shortened docking is completely inhibited [<xref rid="bib105" ref-type="bibr">105</xref>].</p><p id="p0135">Lastly, large oligomers of &#x003b1;-syn preferentially bind multiple VAMP2 proteins, preventing vesicle docking via t-SNAREs and even when &#x003b1;-syn was overexpressed forming only soluble aggregates, SNARE function was impeded [<xref rid="bib130" ref-type="bibr">130</xref>]. This is further supported by a general increase in &#x003b1;-syn oligomers and decrease in SNARE proteins in the cerebrospinal fluid of PD patients [<xref rid="bib131" ref-type="bibr">131</xref>]. However, in the presence of &#x003b1;-syn mutations disruptions of SNARE complex docking or assembly capable of impacting the immune system and specifically immune cell signaling can occur [<xref rid="bib21" ref-type="bibr">21</xref>].</p></sec></sec><sec id="sec4"><label>4</label><title>Inflammaging and PD</title><sec id="sec4.1"><label>4.1</label><title>Inflammasome structure and activation</title><p id="p0140">As previously discussed, the immune response in PD is mediated for the most part by microglia, which secrete cytokines once activated that elicit neuroinflammation. In response to such signaling, a multiprotein complex called an inflammasome is activated which results in secretion of pro-inflammatory factors and activation of the innate immune system [<xref rid="bib132" ref-type="bibr">132</xref>]. Specifically, there are two signals needed for this activation, the first being detection of a damage-associated molecular pattern by a pattern recognition receptor (PRR). The second is the upregulation of necessary genes such as pro-IL-1&#x003b2; and NOD-like receptor protein 3 (NLRP3) a type of cytoplasmic PRR mainly studied in the context of neurodegenerative diseases, age-related animal models, and in the elderly [<xref rid="bib132" ref-type="bibr">[132]</xref>, <xref rid="bib133" ref-type="bibr">[133]</xref>, <xref rid="bib134" ref-type="bibr">[134]</xref>]. This second signal is responsible for the oligomerization of NLRP3 to promote activation of pro-caspase-1 (Cas-1), which cleaves IL-1&#x003b2; and IL-18 precursors to generate their active forms [<xref rid="bib135" ref-type="bibr">135</xref>,<xref rid="bib136" ref-type="bibr">136</xref>]. Together with the TLRs, this defines the &#x003b1;-syn/TLRs/NLRP3/Cas-1 inflammasome axis mediating pro-inflammatory pathways seen in PD [<xref rid="bib85" ref-type="bibr">85</xref>,<xref rid="bib137" ref-type="bibr">137</xref>].</p></sec><sec id="sec4.2"><label>4.2</label><title>Inflammaging and its causes</title><p id="p0145">Inflammaging is a result of an individual's exposure to external and internal stresses that trigger inflammation via the immune system. As we age, this can result in a low-grade, chronic, systemic pro-inflammatory state which has been termed &#x0201c;inflammaging&#x0201d; [<xref rid="bib138" ref-type="bibr">138</xref>]. One possible mechanism is through the accumulation of senescent cells as we age, that results in a senescence-associated secretory phenotype made up of pro-inflammatory cytokines such as IL-6 that contribute to inflammaging [<xref rid="bib139" ref-type="bibr">139</xref>,<xref rid="bib140" ref-type="bibr">140</xref>]. An additional mediator is oxidative stress and production of reactive oxygen species (ROS), which increase as we age and promotes senescence and cell death while also supporting an oxidative state and inflammasome assembly [<xref rid="bib141" ref-type="bibr">141</xref>,<xref rid="bib142" ref-type="bibr">142</xref>]. ROS is a byproduct of mitochondrial aerobic respiration that can impair ATP production. This is supported by reports showing that older organisms have fewer and less efficient mitochondria that produce more ROS compared to younger organisms [<xref rid="bib143" ref-type="bibr">143</xref>,<xref rid="bib144" ref-type="bibr">144</xref>]. On the other hand, senescence and ROS production can be promoted by inflammaging itself, creating a self-propagating loop that is central to understanding the human aging process [<xref rid="bib141" ref-type="bibr">141</xref>].</p></sec><sec id="sec4.3"><label>4.3</label><title>Inflammaging in the brain/neuroinflammaging</title><p id="p0150">Unfortunately, inflammaging can spread systemically and therefore impact the whole organism, including the brain. NLRP3 in the inflammasome may steer inflammaging and primarily cause microglia to produce inflammation-inducing mediators [<xref rid="bib145" ref-type="bibr">145</xref>]. This is suspected because aged mice have elevated levels of the inflammasome machinery, especially NLRP3 in microglia [<xref rid="bib146" ref-type="bibr">146</xref>]. This is supported by the acquired protection from inflammaging and improved cognitive performance after NLRP3 inflammasome removal [<xref rid="bib136" ref-type="bibr">136</xref>,<xref rid="bib147" ref-type="bibr">147</xref>]. As microglial senescence develops with increasing age, there is a corresponding increase in neuroinflammatory factors such as IL-1&#x003b2;, IL-6, and ROS that &#x0201c;prime&#x0201d; microglia and drive neurodegeneration [<xref rid="bib148" ref-type="bibr">148</xref>]. Moreover, when the inflammasome is overactivated it accelerates inflammaging and neurodegeneration in various disease states. For example, aged humans with high levels of inflammasomes experience hypertension, arterial stenosis and overall shorter lifespans [<xref rid="bib149" ref-type="bibr">149</xref>]. Of note, murine models have indicated that age follows a propagation pattern, similar to &#x003b1;-syn in PD. When blood from aged animals was transfused into younger mice, it resulted in decreased synaptic plasticity and memory, while the reverse led to aged mice being rescued from cognitive impairment [<xref rid="bib150" ref-type="bibr">150</xref>,<xref rid="bib151" ref-type="bibr">151</xref>]. Lastly, dopaminergic neurons exhibit increased vulnerability to oxidative stress that becomes more pronounced in aging PD subjects [<xref rid="bib152" ref-type="bibr">152</xref>].</p></sec><sec id="sec4.4"><label>4.4</label><title>Inflammaging and &#x003b1;-syn</title><p id="p0155">Although there is an association between biological aging and inflammation, not everyone develops PD despite age being a major risk factor. Therefore, it would be beneficial to analyze how &#x003b1;-syn is affected by inflammaging to gain a better understanding of processes that lead to PD. In young mice, microglia phagocytose both free and exosome-bound &#x003b1;-syn more efficiently compared to older mice (<xref rid="tbl1" ref-type="table">Table 1</xref>) [<xref rid="bib153" ref-type="bibr">153</xref>]. A marked difference between the two groups is that older mice secrete higher levels of cytokines from microglia indicative of a hyperactivated state [<xref rid="bib153" ref-type="bibr">153</xref>]. The inhibition of exocytosis by &#x003b1;-syn has direct links to SNAREs since soluble monomeric &#x003b1;-syn is still needed for normal SNARE complex assembly and membrane fusion in aging mice. When dopaminergic neurons undergo age-induced oxidative stress, &#x003b1;-syn fibrils promote aggregation and the microglial NLRP3 inflammasome is activated by either of these triggers [<xref rid="bib154" ref-type="bibr">154</xref>]. Interestingly, inhibition of the inflammasome ameliorates PD symptoms, suggesting that the NLRP3 inflammasome may be a source of inflammaging and corresponding PD pathology [<xref rid="bib154" ref-type="bibr">154</xref>]. This aggregation would be made worse during aging due to decreases in pH, which stabilize &#x003b1;-syn dimers [<xref rid="bib155" ref-type="bibr">155</xref>].<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Studies supporting association of &#x003b1;-syn and inflammaging.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Reference</th><th>Main Findings</th><th/></tr></thead><tbody><tr><td align="left">[<xref rid="bib87" ref-type="bibr">87</xref>]</td><td align="left">Early microgliosis associated with &#x003b1;-syn accumulation and neuronal dysfunction.</td><td/></tr><tr><td align="left">[<xref rid="bib86" ref-type="bibr">86</xref>]</td><td align="left">Presence of &#x003b1;-syn:<break/>1) Detrimental to macroautophagy and protein synthesis pathways; 2) Changed immune response and axonal degeneration pathways; 3) Upregulated MHC-II receptor expression and genes for proinflammatory cytokines; 4) Indicated endocytosis, inflammation and axonal function are compromised in early PD stages</td><td/></tr><tr><td align="left">[<xref rid="bib80" ref-type="bibr">80</xref>]</td><td align="left">Increase in microglial MHC-II expression in tandem with &#x003b1;-syn inclusions prior to neurodegeneration.</td><td/></tr><tr><td align="left">[<xref rid="bib90" ref-type="bibr">90</xref>]</td><td align="left">1) WT &#x003b1;-syn activated microglia and promoted autophagy to remove monomers via TLR4; 2) Disruption promoted accumulation of misfolded &#x003b1;-syn resulting in midbrain dopaminergic neuron degeneration.</td><td/></tr><tr><td align="left">[<xref rid="bib95" ref-type="bibr">95</xref>]</td><td align="left">1) Extracellular WT human &#x003b1;&#x02010;syn activated TLR4, resulting in inflammatory responses; 2) Autophagy suppressed in microglia via TLR4&#x02010;dependent p38 and Akt/m TOR signaling cascades that aggravated &#x003b1;&#x02010;syn&#x02010;induced inflammatory responses.</td><td/></tr><tr><td align="left">[<xref rid="bib153" ref-type="bibr">153</xref>]</td><td align="left">1) Compared to old mice, microglia phagocytosed both free and exosome-bound &#x003b1;-syn more efficiently in young mice; 2) Older mice secreted higher levels of cytokines from microglia, consistent with hyperactivated state.</td><td/></tr><tr><td align="left">[<xref rid="bib154" ref-type="bibr">154</xref>]</td><td align="left">1) Both NLRP3 and ASC localized to hypertrophic reactive microglia in PD patients; 2) The kinetics and activation profile of NLRP3 induced by &#x003b1;-syn fibrils was distinguishable from conventional activators; 3) Release of active IL-1&#x003b2; p17, cas-1 p20 and ASC in absence of pyroptosis was unique to NLRP3 activation with &#x003b1;-syn fibrils.</td><td/></tr><tr><td align="left">[<xref rid="bib138" ref-type="bibr">138</xref>]</td><td align="left">1) Rotenone induced &#x003b1;-syn accumulation in both young and aged mouse groups, yet only the latter exhibited neurodegenerative changes with motor impairment; 2) Inflammaging was observed in the OB and striatum of 12-month-old mice compared to 3-month-old mice; 3) Age deemed a critical factor for &#x003b1;-syn induced neuroinflammation and neurodegeneration; 4) Low-dose exposure to rotenone to mimic aging in young mice induced LB inclusions in the brain; 5) Inferred age is pivotal factor in &#x003b1;-syn-induced neuroinflammation and neurodegeneration.</td><td/></tr><tr><td align="left">[<xref rid="bib158" ref-type="bibr">158</xref>]</td><td align="left">1) The C/EBP&#x003b2;/AEP inflammatory pathway age-dependently activated and cleaved &#x003b1;-syn N103 residue to regulate Lewy body-like spread in human &#x003b1;-syn transgenic mice; 2) Deletion of C/EBP&#x003b2; or AEP substantially diminished oxidative stress, neuro-inflammation, and PD pathology.</td><td/></tr><tr><td align="left">[<xref rid="bib159" ref-type="bibr">159</xref>]</td><td align="left">Human &#x003b1;-syn mice that exhibited chronic neuron-specific oxidative stress had significantly higher &#x003b1;-syn aggregate densities than littermate mice.</td><td/></tr><tr><td align="left">[<xref rid="bib160" ref-type="bibr">160</xref>]</td><td align="left">Exogenous &#x003b1;-syn inhibited IL6ST, which in turn inhibited JAK2-STAT3 pathway in microglia while increasing HIF-1&#x003b1; thus accelerating oxidative stress.</td><td/></tr><tr><td align="left">[<xref rid="bib145" ref-type="bibr">145</xref>]</td><td align="left">1) &#x003b1;-syn activated the NLRP3 inflammasome through microglial endocytosis and subsequent lysosomal cathepsin B release; 2) Deficiency of cas-1, part of the NLRP3 inflammasome, significantly inhibited &#x003b1;-syn-induced microglia activation and IL-1&#x003b2; production.</td><td/></tr></tbody></table><table-wrap-foot><fn><p>Key to table abbreviations: ASC&#x000a0;=&#x000a0;apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; TOR&#x000a0;=&#x000a0;target of rapamycin; IL6ST&#x000a0;=&#x000a0;interleukin 6 cytokine family signal transducer; HIF1&#x003b1;&#x000a0;=&#x000a0;hypoxia inducible factor 1 subunit alpha; OB&#x000a0;=&#x000a0;olfactory bulb; AEP&#x000a0;=&#x000a0;asparagine endopeptidase; cas-1&#x000a0;=&#x000a0;caspase-1; PD= Parkinson's disease; TLR4&#x000a0;=&#x000a0;toll-like receptor 4; NLRP3= NOD-like receptor protein 3; WT&#x000a0;=&#x000a0;wild type.</p></fn></table-wrap-foot></table-wrap></p><p id="p0160">Additional mechanisms of age-related &#x003b1;-syn aggregation due to oxidative stress during aging may include direct modification of &#x003b1;-syn such as nitrosylation, truncation, and dimerization, or indirect methods such as autophagy impairment and DNA damage [<xref rid="bib156" ref-type="bibr">156</xref>]. Unfortunately, experimental models of inflammaging in the brain are not well established. However, EAAC1 KO aged mice used to model chronic oxidative stress were characterized by activated c-Abl, a DNA damage response kinase located in the cytosol, which promoted phosphorylation of &#x003b1;-syn resulting in slower autophagy rates [<xref rid="bib156" ref-type="bibr">156</xref>]. Overexpression of &#x003b1;-syn also increased aggregation in aged mice [<xref rid="bib156" ref-type="bibr">156</xref>]. Importantly, a murine hypoxia model indicated that induction of &#x003b1;-syn phosphorylation triggered higher proportion of aggregation and propagation compared the non-phosphorylated form of the protein that resulted in dopaminergic neuronal loss similar to that seen in PD [<xref rid="bib157" ref-type="bibr">157</xref>].</p><p id="p0165">Chemical compounds such as rotenone can simulate inflammaging as that seen in PD but without dopaminergic neuronal loss. In mice, rotenone induced &#x003b1;-syn accumulation in both young and aged mouse groups, yet only the latter exhibited neurodegenerative changes with motor impairment [<xref rid="bib138" ref-type="bibr">138</xref>]. One of these pathways regulating inflammation in response to glial activation is the C/EBP&#x003b2;/AEP pathway induced by rotenone, thus linking it to the active aggregation and cleavage of &#x003b1;-syn [<xref rid="bib158" ref-type="bibr">158</xref>]. Of note, aggregation itself can promote inflammaging as shown in mice [<xref rid="bib159" ref-type="bibr">159</xref>]. Microglia-derived mediators also promote the hyperactivity of glial cells via the STAT3 pathway which can upregulate transcription of genes responsive to hypoxic conditions and cytotoxic damage [<xref rid="bib160" ref-type="bibr">160</xref>]. This pathway can be inhibited by exogenous &#x003b1;-syn through reduction of oxidative stress repair (increasing ROS) by inhibiting IL-6 and STAT3 in microglia (<xref rid="tbl1" ref-type="table">Table 1</xref>) [<xref rid="bib160" ref-type="bibr">160</xref>].</p></sec><sec id="sec4.5"><label>4.5</label><title>Conserved structures and repetitive cycles</title><p id="p0170">Throughout the cell types, proteins, and complexes that have been reviewed, there is a unifying theme of conserved structure and shared function. It is apparent that &#x003b1;-syn structural integrity is an important factor that requires further investigation [<xref rid="bib161" ref-type="bibr">161</xref>]. Likewise, SNAREs are highly conserved and have shown essential to both normal brain physiology and potentially immune responses. This favors the use of animal models to study &#x003b1;-syn since the roles thus far shown to be mediated by this molecule are likely conserved between species. There are feed-forward mechanisms that can be pathological such as the prion-like propagation of &#x003b1;-syn. In this regard, when oligomerization begins, the protein preferentially adds to existing aggregates and drives sigmoidal growth [<xref rid="bib57" ref-type="bibr">57</xref>]. This emphasizes the importance of understanding how a protein necessary in normal cell functioning can lead to disease due to structural or conformational changes. At the cellular level, primed or hyperactive microglia can also set in motion &#x003b1;-syn aggregation which causes inflammation and feeds back further activation of primed microglia [<xref rid="bib148" ref-type="bibr">148</xref>]. The latter also carry out autophagy, but if &#x003b1;-syn oligomers bound to VAMP2 prevent SNARE complex assembly, the aggregates will not be cleared [<xref rid="bib21" ref-type="bibr">21</xref>]. Simultaneously, if dopaminergic neurons needed to inhibit NLRP3 activation are degraded, oligomerization can be exacerbated, leading to enhanced neuronal degradation [<xref rid="bib148" ref-type="bibr">148</xref>].</p><p id="p0175">Consequently, taking these looping mechanisms into account, it is feasible that since aged organisms generally have elevated levels of &#x003b1;-syn, there is a predisposition to greater numbers of inflammasomes (specifically NLRP3 in microglia) in aged subjects [<xref rid="bib146" ref-type="bibr">146</xref>,<xref rid="bib162" ref-type="bibr">162</xref>]. To draw a connection of how inflammaging can lead to excessive inflammasome activation, it has been suggested that inflammaging is capable of stimulating the lymphatic system through impairment of the blood-brain barrier secondary to ROS-mediated injury allowing entry of inflammatory mediators into the CNS [<xref rid="bib136" ref-type="bibr">136</xref>]. Once inside the brain, microglial NLRP3 inflammasome activation increases &#x003b1;-syn aggregation and expands ROS synthesis stimulating &#x003b1;-syn aggregation via oxidation [<xref rid="bib136" ref-type="bibr">136</xref>]. The fibrillar form of &#x003b1;-syn can, in turn, impair proper mitochondrial function and cause further ROS production, thus driving a higher inflammatory microglial state [<xref rid="bib144" ref-type="bibr">144</xref>]. As mentioned earlier, &#x003b1;-syn aggregation can inhibit SNARE complex assembly and access to vesicles, which can result in dysfunction of the immune system (including microglial autophagy), signaling pathways and expand further the inflammatory cycle [<xref rid="bib163" ref-type="bibr">163</xref>]. Dopaminergic neurons may have greater susceptibility to oxidation and consequently degradation, events that drive PD progression through promotion of inflammation [<xref rid="bib144" ref-type="bibr">144</xref>,<xref rid="bib159" ref-type="bibr">159</xref>].</p></sec><sec id="sec4.6"><label>4.6</label><title>Limitations and future directions</title><p id="p0180">Despite a number of technical limitations, researchers should be able to study though the induction of chronic oxidative stress, how this process mimics inflammaging while evaluating its effects on &#x003b1;-syn aggregation. Mimicking inflammaging would ideally be a drawn-out process, due to the requirement of simulating an organism's natural aging process. For example, low-dose exposure to rotenone in young mice induces LB inclusions in the brain [<xref rid="bib138" ref-type="bibr">138</xref>]. However, this would not be practical to do during the life of an animal to mimic aging progression. The use of chemicals introduces another variable difficult to control for, which is the extent that off-target effects impact other organ systems. These are just a few of the potential challenges encountered developing proper experimental models to study these interactions.</p><p id="p0185">One possibility may be the use of brain organoids to model PD progression in human tissue, especially in light of advances in regenerative medicine that may allow for portions of the brain involved in PD to be analyzed [<xref rid="bib164" ref-type="bibr">164</xref>]. Investigation into the inflammatory state and &#x003b1;-syn profile of the elderly could yield more information on why some older humans develop PD while others do not. Results from such studies could then be used to identify biomarkers that increase the propensity for PD diagnosis or development of symptomatology. Studies of age-related treatments would also be possible since blood donations from young mice has been able to rescue cognitive function in aged mice [<xref rid="bib151" ref-type="bibr">151</xref>]. These findings ought to stimulate the interest of researchers to explore how this can give origins to new treatments for PD patients.</p><p id="p0190">In summary, &#x003b1;-syn represents an important protein that not only leads to PD pathology but that during normal physiology mediates important processes not limited to the CNS. Indeed, its role as an important mediator in the maturation of immune cells, interaction with SNARE complexes but above all inflammatory mediators, make this protein's study essential to establish not only a more complete knowledge of its function but potentially develop targeted therapeutic approaches that lead to not only improvement of PD function but addresses chronic inflammatory mechanisms playing out during aging.</p></sec></sec><sec id="sec5"><title>CRediT authorship contribution statement</title><p id="p0195"><bold>Genevi&#x000e8;ve L. Putnam:</bold> Writing &#x02013; original draft, Investigation, Formal analysis, Data curation. <bold>Robert W. Maitta:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0200">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Robert Maitta is Associate Editor for Heliyon. All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Dexter</surname><given-names>D.T.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name></person-group><article-title>Parkinson disease: from pathology to molecular disease mechanisms</article-title><source>Free Radic. Biol. Med.</source><volume>62</volume><year>2013</year><fpage>132</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">23380027</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Parkinson's disease</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/parkinson-disease" id="intref0015">https://www.who.int/news-room/fact-sheets/detail/parkinson-disease</ext-link><year>2023</year></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="other" id="sref3"><person-group person-group-type="author"><collab>National Institutes of Health</collab></person-group><article-title>Parkinson's disease: challenges, progress, and Promise</article-title><ext-link ext-link-type="uri" xlink:href="https://www.ninds.nih.gov/current-research/focusdisorders/parkinsonsdiseaseresearch/parkinsons-disease-challenges-progress-and-promise" id="intref0020">https://www.ninds.nih.gov/current-research/focusdisorders/parkinsonsdiseaseresearch/parkinsons-disease-challenges-progress-and-promise</ext-link><year>2023</year></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><collab>G.B.D.P.s.D. Collaborators</collab></person-group><article-title>Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Neurol.</source><volume>17</volume><issue>11</issue><year>2018</year><fpage>939</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">30287051</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>Z.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Duan</surname><given-names>D.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Nong</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019</article-title><source>Front. Public Health</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">776847</object-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>M.H.</given-names></name><name><surname>Lavedan</surname><given-names>C.</given-names></name><name><surname>Leroy</surname><given-names>E.</given-names></name><name><surname>Ide</surname><given-names>S.E.</given-names></name><name><surname>Dehejia</surname><given-names>A.</given-names></name><name><surname>Dutra</surname><given-names>A.</given-names></name><name><surname>Pike</surname><given-names>B.</given-names></name><name><surname>Root</surname><given-names>H.</given-names></name><name><surname>Rubenstein</surname><given-names>J.</given-names></name><name><surname>Boyer</surname><given-names>R.</given-names></name><name><surname>Stenroos</surname><given-names>E.S.</given-names></name><name><surname>Chandrasekharappa</surname><given-names>S.</given-names></name><name><surname>Athanassiadou</surname><given-names>A.</given-names></name><name><surname>Papapetropoulos</surname><given-names>T.</given-names></name><name><surname>Johnson</surname><given-names>W.G.</given-names></name><name><surname>Lazzarini</surname><given-names>A.M.</given-names></name><name><surname>Duvoisin</surname><given-names>R.C.</given-names></name><name><surname>Di Iorio</surname><given-names>G.</given-names></name><name><surname>Golbe</surname><given-names>L.I.</given-names></name><name><surname>Nussbaum</surname><given-names>R.L.</given-names></name></person-group><article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson's disease</article-title><source>Science</source><volume>276</volume><issue>5321</issue><year>1997</year><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">9197268</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Spillantini</surname><given-names>M.G.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>Identification of two distinct synucleins from human brain</article-title><source>FEBS Lett.</source><volume>345</volume><issue>1</issue><year>1994</year><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">8194594</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>M.G.</given-names></name><name><surname>Schmidt</surname><given-names>M.L.</given-names></name><name><surname>Lee</surname><given-names>V.M.</given-names></name><name><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><volume>388</volume><issue>6645</issue><year>1997</year><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">9278044</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Surguchov</surname><given-names>A.J.</given-names></name></person-group><article-title>Synucleins: are they two&#x02010;edged swords?</article-title><volume>91</volume><issue>2</issue><year>2013</year><fpage>161</fpage><lpage>166</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Ltic</surname><given-names>S.</given-names></name><name><surname>Perovic</surname><given-names>M.</given-names></name><name><surname>Mladenovic</surname><given-names>A.</given-names></name><name><surname>Raicevic</surname><given-names>N.</given-names></name><name><surname>Ruzdijic</surname><given-names>S.</given-names></name><name><surname>Rakic</surname><given-names>L.</given-names></name><name><surname>Kanazir</surname><given-names>S.</given-names></name></person-group><article-title>Alpha-synuclein is expressed in different tissues during human fetal development</article-title><source>J. Mol. Neurosci.</source><volume>22</volume><issue>3</issue><year>2004</year><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">14997013</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>K.</given-names></name><name><surname>Saitoh</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name></person-group><article-title>Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>205</volume><issue>2</issue><year>1994</year><fpage>1366</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">7802671</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Vekrellis</surname><given-names>K.</given-names></name><name><surname>Xilouri</surname><given-names>M.</given-names></name><name><surname>Emmanouilidou</surname><given-names>E.</given-names></name><name><surname>Rideout</surname><given-names>H.J.</given-names></name><name><surname>Stefanis</surname><given-names>L.</given-names></name></person-group><article-title>Pathological roles of alpha-synuclein in neurological disorders</article-title><source>Lancet Neurol.</source><volume>10</volume><issue>11</issue><year>2011</year><fpage>1015</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">22014436</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Surguchov</surname><given-names>A.</given-names></name><name><surname>Surguchev</surname><given-names>A.</given-names></name></person-group><article-title>Synucleins: new data on misfolding, aggregation and role in diseases</article-title><source>Biomedicines</source><volume>10</volume><issue>12</issue><year>2022</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Sacino</surname><given-names>A.N.</given-names></name><name><surname>Thomas</surname><given-names>M.A.</given-names></name><name><surname>Ceballos-Diaz</surname><given-names>C.</given-names></name><name><surname>Cruz</surname><given-names>P.E.</given-names></name><name><surname>Rosario</surname><given-names>A.M.</given-names></name><name><surname>Lewis</surname><given-names>J.</given-names></name><name><surname>Giasson</surname><given-names>B.I.</given-names></name><name><surname>Golde</surname><given-names>T.E.</given-names></name></person-group><article-title>Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures</article-title><source>Mol. Neurodegener.</source><volume>8</volume><year>2013</year><fpage>17</fpage><pub-id pub-id-type="pmid">23714769</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Ruggeri</surname><given-names>F.S.</given-names></name><name><surname>Flagmeier</surname><given-names>P.</given-names></name><name><surname>Kumita</surname><given-names>J.R.</given-names></name><name><surname>Meisl</surname><given-names>G.</given-names></name><name><surname>Chirgadze</surname><given-names>D.Y.</given-names></name><name><surname>Bongiovanni</surname><given-names>M.N.</given-names></name><name><surname>Knowles</surname><given-names>T.P.J.</given-names></name><name><surname>Dobson</surname><given-names>C.M.</given-names></name></person-group><article-title>The influence of pathogenic mutations in alpha-synuclein on biophysical and structural characteristics of amyloid fibrils</article-title><source>ACS Nano</source><volume>14</volume><issue>5</issue><year>2020</year><fpage>5213</fpage><lpage>5222</lpage><pub-id pub-id-type="pmid">32159944</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Stefaniuk</surname><given-names>C.M.</given-names></name><name><surname>Hong</surname><given-names>H.</given-names></name><name><surname>Harding</surname><given-names>C.V.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>alpha-Synuclein concentration increases over time in plasma supernatant of single donor platelets</article-title><source>Eur. J. Haematol.</source><year>2018</year></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Maitta</surname><given-names>R.W.</given-names></name><name><surname>Wolgast</surname><given-names>L.R.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Bhattacharyya</surname><given-names>P.</given-names></name><name><surname>Gong</surname><given-names>J.Z.</given-names></name><name><surname>Sunkara</surname><given-names>J.</given-names></name><name><surname>Albanese</surname><given-names>J.M.</given-names></name><name><surname>Pizzolo</surname><given-names>J.G.</given-names></name><name><surname>Cannizzaro</surname><given-names>L.A.</given-names></name><name><surname>Ramesh</surname><given-names>K.H.</given-names></name><name><surname>Ratech</surname><given-names>H.</given-names></name></person-group><article-title>Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia</article-title><source>Am. J. Hematol.</source><volume>86</volume><issue>2</issue><year>2011</year><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">21264917</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Shameli</surname><given-names>A.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Shyu</surname><given-names>S.</given-names></name><name><surname>Sumodi</surname><given-names>J.</given-names></name><name><surname>Meyerson</surname><given-names>H.J.</given-names></name><name><surname>Harding</surname><given-names>C.V.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>A critical role for alpha-synuclein in development and function of T lymphocytes</article-title><source>Immunobiology</source><volume>221</volume><issue>2</issue><year>2016</year><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">26517968</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Shameli</surname><given-names>A.</given-names></name><name><surname>Harding</surname><given-names>C.V.</given-names></name><name><surname>Meyerson</surname><given-names>H.J.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>Late stages of hematopoiesis and B cell lymphopoiesis are regulated by alpha-synuclein, a key player in Parkinson's disease</article-title><source>Immunobiology</source><volume>219</volume><issue>11</issue><year>2014</year><fpage>836</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">25092570</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Tashkandi</surname><given-names>H.</given-names></name><name><surname>Shameli</surname><given-names>A.</given-names></name><name><surname>Harding</surname><given-names>C.V.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>Ultrastructural changes in peripheral blood leukocytes in &#x003b1;-synuclein knockout mice</article-title><source>Blood Cell Mol. Dis.</source><year>2018</year></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>Y.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>Alpha synuclein in hematopoiesis and immunity</article-title><source>Heliyon</source><volume>5</volume><issue>10</issue><year>2019</year><object-id pub-id-type="publisher-id">e02590</object-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Stefaniuk</surname><given-names>C.M.</given-names></name><name><surname>Schlegelmilch</surname><given-names>J.</given-names></name><name><surname>Meyerson</surname><given-names>H.J.</given-names></name><name><surname>Harding</surname><given-names>C.V.</given-names></name><name><surname>Maitta</surname><given-names>R.W.</given-names></name></person-group><article-title>Initial assessment of alpha-synuclein structure in platelets</article-title><source>J. Thromb. Thrombolysis</source><volume>53</volume><issue>4</issue><year>2022</year><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">34797472</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Van Den Berge</surname><given-names>N.</given-names></name><name><surname>Ferreira</surname><given-names>N.</given-names></name><name><surname>Mikkelsen</surname><given-names>T.W.</given-names></name><name><surname>Alstrup</surname><given-names>A.K.O.</given-names></name><name><surname>Tamguney</surname><given-names>G.</given-names></name><name><surname>Karlsson</surname><given-names>P.</given-names></name><name><surname>Terkelsen</surname><given-names>A.J.</given-names></name><name><surname>Nyengaard</surname><given-names>J.R.</given-names></name><name><surname>Jensen</surname><given-names>P.H.</given-names></name><name><surname>Borghammer</surname><given-names>P.</given-names></name></person-group><article-title>Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats</article-title><source>Brain</source><volume>144</volume><issue>6</issue><year>2021</year><fpage>1853</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">33880502</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>C.</given-names></name><name><surname>Bonafe</surname><given-names>M.</given-names></name><name><surname>Valensin</surname><given-names>S.</given-names></name><name><surname>Olivieri</surname><given-names>F.</given-names></name><name><surname>De Luca</surname><given-names>M.</given-names></name><name><surname>Ottaviani</surname><given-names>E.</given-names></name><name><surname>De Benedictis</surname><given-names>G.</given-names></name></person-group><article-title>Inflamm-aging. An evolutionary perspective on immunosenescence</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>908</volume><year>2000</year><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">10911963</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Soraci</surname><given-names>L.</given-names></name><name><surname>Corsonello</surname><given-names>A.</given-names></name><name><surname>Paparazzo</surname><given-names>E.</given-names></name><name><surname>Montesanto</surname><given-names>A.</given-names></name><name><surname>Piacenza</surname><given-names>F.</given-names></name><name><surname>Olivieri</surname><given-names>F.</given-names></name><name><surname>Gambuzza</surname><given-names>M.E.</given-names></name><name><surname>Savedra</surname><given-names>E.V.</given-names></name><name><surname>Marino</surname><given-names>S.</given-names></name><name><surname>Lattanzio</surname><given-names>F.</given-names></name><name><surname>Biscetti</surname><given-names>L.</given-names></name></person-group><article-title>Neuroinflammaging: a tight line between normal aging and age-related neurodegenerative disorders</article-title><source>Aging Dis</source><year>2024</year></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Sudhof</surname><given-names>T.C.</given-names></name></person-group><article-title>Cell biology and pathophysiology of alpha-synuclein</article-title><source>Cold Spring Harb Perspect Med</source><volume>8</volume><issue>3</issue><year>2018</year></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Auluck</surname><given-names>P.K.</given-names></name><name><surname>Caraveo</surname><given-names>G.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>26</volume><year>2010</year><fpage>211</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">20500090</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Afitska</surname><given-names>K.</given-names></name><name><surname>Fucikova</surname><given-names>A.</given-names></name><name><surname>Shvadchak</surname><given-names>V.V.</given-names></name><name><surname>Yushchenko</surname><given-names>D.A.</given-names></name></person-group><article-title>Modification of C Terminus provides new insights into the mechanism of alpha-synuclein aggregation</article-title><source>Biophys. J.</source><volume>113</volume><issue>10</issue><year>2017</year><fpage>2182</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">28939194</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Teive</surname><given-names>H.A.</given-names></name><name><surname>Raskin</surname><given-names>S.</given-names></name><name><surname>Iwamoto</surname><given-names>F.M.</given-names></name><name><surname>Germiniani</surname><given-names>F.M.</given-names></name><name><surname>Baran</surname><given-names>M.H.</given-names></name><name><surname>Werneck</surname><given-names>L.C.</given-names></name><name><surname>Allan</surname><given-names>N.</given-names></name><name><surname>Quagliato</surname><given-names>E.</given-names></name><name><surname>Leroy</surname><given-names>E.</given-names></name><name><surname>Ide</surname><given-names>S.E.</given-names></name><name><surname>Polymeropoulos</surname><given-names>M.H.</given-names></name></person-group><article-title>The G209A mutation in the alpha-synuclein gene in Brazilian families with Parkinson's disease</article-title><source>Arq Neuropsiquiatr</source><volume>59</volume><issue>3-B</issue><year>2001</year><fpage>722</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">11593272</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Hoffman-Zacharska</surname><given-names>D.</given-names></name><name><surname>Koziorowski</surname><given-names>D.</given-names></name><name><surname>Ross</surname><given-names>O.A.</given-names></name><name><surname>Milewski</surname><given-names>M.</given-names></name><name><surname>Poznanski</surname><given-names>J.A.</given-names></name><name><surname>Jurek</surname><given-names>M.</given-names></name><name><surname>Wszolek</surname><given-names>Z.K.</given-names></name><name><surname>Soto-Ortolaza</surname><given-names>A.</given-names></name><name><surname>Awek</surname><given-names>J.A.S.</given-names></name><name><surname>Janik</surname><given-names>P.</given-names></name><name><surname>Jamrozik</surname><given-names>Z.</given-names></name><name><surname>Potulska-Chromik</surname><given-names>A.</given-names></name><name><surname>Jasinska-Myga</surname><given-names>B.</given-names></name><name><surname>Opala</surname><given-names>G.</given-names></name><name><surname>Krygowska-Wajs</surname><given-names>A.</given-names></name><name><surname>Czyzewski</surname><given-names>K.</given-names></name><name><surname>Dickson</surname><given-names>D.W.</given-names></name><name><surname>Bal</surname><given-names>J.</given-names></name><name><surname>Friedman</surname><given-names>A.</given-names></name></person-group><article-title>Novel A18T and pA29S substitutions in alpha-synuclein may be associated with sporadic Parkinson's disease</article-title><source>Parkinsonism Relat. Disorders</source><volume>19</volume><issue>11</issue><year>2013</year><fpage>1057</fpage><lpage>1060</lpage></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Maltseva</surname><given-names>S.</given-names></name><name><surname>Kerr</surname><given-names>D.</given-names></name><name><surname>Turke</surname><given-names>M.</given-names></name><name><surname>Adams</surname><given-names>E.J.</given-names></name><name><surname>Lee</surname><given-names>K.Y.C.</given-names></name></person-group><article-title>Parkinson's disease-associated mutations in alpha-synuclein alters its lipid-bound state</article-title><source>Biophys. J.</source><volume>123</volume><issue>12</issue><year>2024</year><fpage>1610</fpage><lpage>1619</lpage><pub-id pub-id-type="pmid">38702883</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Flagmeier</surname><given-names>P.</given-names></name><name><surname>Meisl</surname><given-names>G.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><name><surname>Knowles</surname><given-names>T.P.</given-names></name><name><surname>Dobson</surname><given-names>C.M.</given-names></name><name><surname>Buell</surname><given-names>A.K.</given-names></name><name><surname>Galvagnion</surname><given-names>C.</given-names></name></person-group><article-title>Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of alpha-synuclein aggregation</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>113</volume><issue>37</issue><year>2016</year><fpage>10328</fpage><lpage>10333</lpage><pub-id pub-id-type="pmid">27573854</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Rutherford</surname><given-names>N.J.</given-names></name><name><surname>Moore</surname><given-names>B.D.</given-names></name><name><surname>Golde</surname><given-names>T.E.</given-names></name><name><surname>Giasson</surname><given-names>B.I.</given-names></name></person-group><article-title>Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of &#x003b1;&#x02010;synuclein</article-title><volume>131</volume><issue>6</issue><year>2014</year><fpage>859</fpage><lpage>867</lpage></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Appel&#x02010;Cresswell</surname><given-names>S.</given-names></name><name><surname>Vilarino&#x02010;Guell</surname><given-names>C.</given-names></name><name><surname>Encarnacion</surname><given-names>M.</given-names></name><name><surname>Sherman</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>I.</given-names></name><name><surname>Shah</surname><given-names>B.</given-names></name><name><surname>Weir</surname><given-names>D.</given-names></name><name><surname>Thompson</surname><given-names>C.</given-names></name><name><surname>Szu&#x02010;Tu</surname><given-names>C.</given-names></name><name><surname>Trinh</surname><given-names>J.J.M.d.</given-names></name></person-group><article-title>Alpha&#x02010;synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease</article-title><volume>28</volume><issue>6</issue><year>2013</year><fpage>811</fpage><lpage>813</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Zarranz</surname><given-names>J.J.</given-names></name><name><surname>Alegre</surname><given-names>J.</given-names></name><name><surname>G&#x000f3;mez&#x02010;Esteban</surname><given-names>J.C.</given-names></name><name><surname>Lezcano</surname><given-names>E.</given-names></name><name><surname>Ros</surname><given-names>R.</given-names></name><name><surname>Ampuero</surname><given-names>I.</given-names></name><name><surname>Vidal</surname><given-names>L.</given-names></name><name><surname>Hoenicka</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>O.</given-names></name><name><surname>Atar&#x000e9;s</surname><given-names>B.</given-names></name><name><surname>Society</surname><given-names>t.C.N.</given-names></name></person-group><article-title>The new mutation, E46K, of &#x003b1;&#x02010;synuclein causes Parkinson and Lewy body</article-title><source>Dementia</source><volume>55</volume><issue>2</issue><year>2004</year><fpage>164</fpage><lpage>173</lpage></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Kiely</surname><given-names>A.P.</given-names></name><name><surname>Asi</surname><given-names>Y.T.</given-names></name><name><surname>Kara</surname><given-names>E.</given-names></name><name><surname>Limousin</surname><given-names>P.</given-names></name><name><surname>Ling</surname><given-names>H.</given-names></name><name><surname>Lewis</surname><given-names>P.</given-names></name><name><surname>Proukakis</surname><given-names>C.</given-names></name><name><surname>Quinn</surname><given-names>N.</given-names></name><name><surname>Lees</surname><given-names>A.J.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Revesz</surname><given-names>T.</given-names></name><name><surname>Houlden</surname><given-names>H.</given-names></name><name><surname>Holton</surname><given-names>J.L.</given-names></name></person-group><article-title>alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?</article-title><source>Acta Neuropathol.</source><volume>125</volume><issue>5</issue><year>2013</year><fpage>753</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">23404372</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Appel-Cresswell</surname><given-names>S.</given-names></name><name><surname>Vilarino-Guell</surname><given-names>C.</given-names></name><name><surname>Encarnacion</surname><given-names>M.</given-names></name><name><surname>Sherman</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>I.</given-names></name><name><surname>Shah</surname><given-names>B.</given-names></name><name><surname>Weir</surname><given-names>D.</given-names></name><name><surname>Thompson</surname><given-names>C.</given-names></name><name><surname>Szu-Tu</surname><given-names>C.</given-names></name><name><surname>Trinh</surname><given-names>J.</given-names></name><name><surname>Aasly</surname><given-names>J.O.</given-names></name><name><surname>Rajput</surname><given-names>A.</given-names></name><name><surname>Rajput</surname><given-names>A.H.</given-names></name><name><surname>Jon Stoessl</surname><given-names>A.</given-names></name><name><surname>Farrer</surname><given-names>M.J.</given-names></name></person-group><article-title>Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease</article-title><source>Mov. Disord.</source><volume>28</volume><issue>6</issue><year>2013</year><fpage>811</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">23457019</pub-id>
</element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Devine</surname><given-names>M.J.</given-names></name><name><surname>Gwinn</surname><given-names>K.</given-names></name><name><surname>Singleton</surname><given-names>A.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name></person-group><article-title>Parkinson's disease and alpha-synuclein expression</article-title><source>Mov. Disord.</source><volume>26</volume><issue>12</issue><year>2011</year><fpage>2160</fpage><lpage>2168</lpage><pub-id pub-id-type="pmid">21887711</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Rutherford</surname><given-names>N.J.</given-names></name><name><surname>Moore</surname><given-names>B.D.</given-names></name><name><surname>Golde</surname><given-names>T.E.</given-names></name><name><surname>Giasson</surname><given-names>B.I.</given-names></name></person-group><article-title>Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein</article-title><source>J. Neurochem.</source><volume>131</volume><issue>6</issue><year>2014</year><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">24984882</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>H.</given-names></name><name><surname>Hirano</surname><given-names>M.</given-names></name><name><surname>Stoessl</surname><given-names>A.J.</given-names></name><name><surname>Imamichi</surname><given-names>Y.</given-names></name><name><surname>Ikeda</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Funayama</surname><given-names>M.</given-names></name><name><surname>Yamada</surname><given-names>I.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Sossi</surname><given-names>V.</given-names></name><name><surname>Farrer</surname><given-names>M.J.</given-names></name><name><surname>Nishioka</surname><given-names>K.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name></person-group><article-title>Homozygous alpha-synuclein p.A53V in familial Parkinson's disease</article-title><source>Neurobiol. Aging</source><volume>57</volume><year>2017</year><comment>248 e7-248 e12</comment></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Fan</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Distinct effects of familial Parkinson's disease-associated mutations on alpha-synuclein phase separation and amyloid aggregation</article-title><source>Biomolecules</source><volume>13</volume><issue>5</issue><year>2023</year></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>S.</given-names></name><name><surname>Sahay</surname><given-names>S.</given-names></name><name><surname>Maji</surname><given-names>S.K.</given-names></name></person-group><article-title>alpha-Synuclein misfolding and aggregation: implications in Parkinson's disease pathogenesis</article-title><source>Biochim. Biophys. Acta, Proteins Proteomics</source><volume>1867</volume><issue>10</issue><year>2019</year><fpage>890</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">30853581</pub-id>
</element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M.M.</given-names></name><name><surname>Rodrigues</surname><given-names>F.C.</given-names></name><name><surname>Leite</surname><given-names>M.A.</given-names></name><name><surname>Campos Junior</surname><given-names>M.</given-names></name><name><surname>Rosso</surname><given-names>A.L.</given-names></name><name><surname>Nicaretta</surname><given-names>D.H.</given-names></name><name><surname>Pereira</surname><given-names>J.S.</given-names></name><name><surname>Silva</surname><given-names>D.J.</given-names></name><name><surname>Della Coletta</surname><given-names>M.V.</given-names></name><name><surname>Vasconcellos</surname><given-names>L.F.</given-names></name><name><surname>Abreu</surname><given-names>G.M.</given-names></name><name><surname>Dos Santos</surname><given-names>J.M.</given-names></name><name><surname>Santos-Reboucas</surname><given-names>C.B.</given-names></name></person-group><article-title>Parkinson disease: alpha-synuclein mutational screening and new clinical insight into the p.E46K mutation</article-title><source>Parkinsonism Relat. Disorders</source><volume>21</volume><issue>6</issue><year>2015</year><fpage>586</fpage><lpage>589</lpage></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>G.A.P.</given-names></name><name><surname>Silva</surname><given-names>J.L.</given-names></name></person-group><article-title>Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease</article-title><source>Commun. Biol.</source><volume>2</volume><year>2019</year><fpage>374</fpage><pub-id pub-id-type="pmid">31633065</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Ohgita</surname><given-names>T.</given-names></name><name><surname>Namba</surname><given-names>N.</given-names></name><name><surname>Kono</surname><given-names>H.</given-names></name><name><surname>Shimanouchi</surname><given-names>T.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of alpha-synuclein</article-title><source>Sci. Rep.</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>6770</fpage><pub-id pub-id-type="pmid">35474118</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Sahay</surname><given-names>S.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name><name><surname>Singh</surname><given-names>P.K.</given-names></name><name><surname>Maji</surname><given-names>S.K.</given-names></name></person-group><article-title>Alteration of structure and aggregation of alpha-synuclein by familial Parkinson's disease associated mutations</article-title><source>Curr. Protein Pept. Sci.</source><volume>18</volume><issue>7</issue><year>2017</year><fpage>656</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">26972727</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>T.</given-names></name><name><surname>Tochio</surname><given-names>N.</given-names></name><name><surname>Utsunomiya-Tate</surname><given-names>N.</given-names></name></person-group><article-title>Physicochemical characterization of the G51D mutation of alpha-synuclein that is responsible for its severe cytotoxicity</article-title><source>Neurosci. Lett.</source><volume>760</volume><year>2021</year><object-id pub-id-type="publisher-id">136077</object-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>R.</given-names></name><name><surname>Kuhn</surname><given-names>W.</given-names></name><name><surname>Muller</surname><given-names>T.</given-names></name><name><surname>Woitalla</surname><given-names>D.</given-names></name><name><surname>Graeber</surname><given-names>M.</given-names></name><name><surname>Kosel</surname><given-names>S.</given-names></name><name><surname>Przuntek</surname><given-names>H.</given-names></name><name><surname>Epplen</surname><given-names>J.T.</given-names></name><name><surname>Schols</surname><given-names>L.</given-names></name><name><surname>Riess</surname><given-names>O.</given-names></name></person-group><article-title>Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease</article-title><source>Nat. Genet.</source><volume>18</volume><issue>2</issue><year>1998</year><fpage>106</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">9462735</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>D.R.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Hughes</surname><given-names>M.P.</given-names></name><name><surname>Sawaya</surname><given-names>M.R.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Eisenberg</surname><given-names>D.S.</given-names></name></person-group><article-title>The alpha-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume><issue>7</issue><year>2020</year><fpage>3592</fpage><lpage>3602</lpage><pub-id pub-id-type="pmid">32015135</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>P.H.</given-names></name><name><surname>Nielsen</surname><given-names>M.S.</given-names></name><name><surname>Jakes</surname><given-names>R.</given-names></name><name><surname>Dotti</surname><given-names>C.G.</given-names></name><name><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation</article-title><source>J. Biol. Chem.</source><volume>273</volume><issue>41</issue><year>1998</year><fpage>26292</fpage><lpage>26294</lpage><pub-id pub-id-type="pmid">9756856</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>A.R.</given-names></name><name><surname>Hill</surname><given-names>J.</given-names></name><name><surname>Utton</surname><given-names>M.A.</given-names></name><name><surname>Asuni</surname><given-names>A.A.</given-names></name><name><surname>Ackerley</surname><given-names>S.</given-names></name><name><surname>Grierson</surname><given-names>A.J.</given-names></name><name><surname>Miller</surname><given-names>C.C.</given-names></name><name><surname>Davies</surname><given-names>A.M.</given-names></name><name><surname>Buchman</surname><given-names>V.L.</given-names></name><name><surname>Anderton</surname><given-names>B.H.</given-names></name><name><surname>Hanger</surname><given-names>D.P.</given-names></name></person-group><article-title>Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons</article-title><source>J. Cell Sci.</source><volume>117</volume><issue>Pt 7</issue><year>2004</year><fpage>1017</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">14996933</pub-id>
</element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Ramalingam</surname><given-names>N.</given-names></name><name><surname>Brontesi</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>S.X.</given-names></name><name><surname>Selkoe</surname><given-names>D.J.</given-names></name><name><surname>Dettmer</surname><given-names>U.</given-names></name></person-group><article-title>Dynamic reversibility of alpha-synuclein serine-129 phosphorylation is impaired in synucleinopathy models</article-title><source>EMBO Rep.</source><volume>24</volume><issue>12</issue><year>2023</year><object-id pub-id-type="publisher-id">e57145</object-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Koros</surname><given-names>C.</given-names></name><name><surname>Strohaker</surname><given-names>T.</given-names></name><name><surname>Schulte</surname><given-names>C.</given-names></name><name><surname>Bozi</surname><given-names>M.</given-names></name><name><surname>Varvaresos</surname><given-names>S.</given-names></name><name><surname>Ibanez de Opakua</surname><given-names>A.</given-names></name><name><surname>Simitsi</surname><given-names>A.M.</given-names></name><name><surname>Bougea</surname><given-names>A.</given-names></name><name><surname>Voumvourakis</surname><given-names>K.</given-names></name><name><surname>Maniati</surname><given-names>M.</given-names></name><name><surname>Papageorgiou</surname><given-names>S.G.</given-names></name><name><surname>Hauser</surname><given-names>A.K.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Zweckstetter</surname><given-names>M.</given-names></name><name><surname>Stefanis</surname><given-names>L.</given-names></name><name><surname>Gasser</surname><given-names>T.</given-names></name></person-group><article-title>A novel SNCA A30G mutation causes familial Parkinson's disease</article-title><source>Mov. Disord.</source><volume>36</volume><issue>7</issue><year>2021</year><fpage>1624</fpage><lpage>1633</lpage><pub-id pub-id-type="pmid">33617693</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Das</surname><given-names>D.</given-names></name><name><surname>Mattaparthi</surname><given-names>V.S.K.</given-names></name></person-group><article-title>Conformational dynamics of A30G alpha-synuclein that causes familial Parkinson disease</article-title><source>J. Biomol. Struct. Dyn.</source><volume>41</volume><issue>24</issue><year>2023</year><fpage>14702</fpage><lpage>14714</lpage><pub-id pub-id-type="pmid">36961209</pub-id>
</element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Pasanen</surname><given-names>P.</given-names></name><name><surname>Myllykangas</surname><given-names>L.</given-names></name><name><surname>Siitonen</surname><given-names>M.</given-names></name><name><surname>Raunio</surname><given-names>A.</given-names></name><name><surname>Kaakkola</surname><given-names>S.</given-names></name><name><surname>Lyytinen</surname><given-names>J.</given-names></name><name><surname>Tienari</surname><given-names>P.J.</given-names></name><name><surname>Poyhonen</surname><given-names>M.</given-names></name><name><surname>Paetau</surname><given-names>A.</given-names></name></person-group><article-title>Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology</article-title><source>Neurobiol. Aging</source><volume>35</volume><issue>9</issue><year>2014</year><comment>2180 e1-5</comment></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>I.J.</given-names></name><name><surname>Pervaiz</surname><given-names>N.</given-names></name><name><surname>Abbasi</surname><given-names>A.A.</given-names></name></person-group><article-title>The Parkinson Disease gene SNCA: evolutionary and structural insights with pathological implication</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><object-id pub-id-type="publisher-id">24475</object-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Cremades</surname><given-names>N.</given-names></name><name><surname>Cohen</surname><given-names>S.I.</given-names></name><name><surname>Deas</surname><given-names>E.</given-names></name><name><surname>Abramov</surname><given-names>A.Y.</given-names></name><name><surname>Chen</surname><given-names>A.Y.</given-names></name><name><surname>Orte</surname><given-names>A.</given-names></name><name><surname>Sandal</surname><given-names>M.</given-names></name><name><surname>Clarke</surname><given-names>R.W.</given-names></name><name><surname>Dunne</surname><given-names>P.</given-names></name><name><surname>Aprile</surname><given-names>F.A.</given-names></name><name><surname>Bertoncini</surname><given-names>C.W.</given-names></name><name><surname>Wood</surname><given-names>N.W.</given-names></name><name><surname>Knowles</surname><given-names>T.P.</given-names></name><name><surname>Dobson</surname><given-names>C.M.</given-names></name><name><surname>Klenerman</surname><given-names>D.</given-names></name></person-group><article-title>Direct observation of the interconversion of normal and toxic forms of alpha-synuclein</article-title><source>Cell</source><volume>149</volume><issue>5</issue><year>2012</year><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">22632969</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>T.B.</given-names></name><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Park</surname><given-names>S.S.</given-names></name><name><surname>Lee</surname><given-names>D.S.</given-names></name><name><surname>Min</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>Y.K.</given-names></name><name><surname>Kim</surname><given-names>S.E.</given-names></name><name><surname>Kim</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Cho</surname><given-names>J.</given-names></name><name><surname>Jeon</surname><given-names>B.S.</given-names></name></person-group><article-title>alpha-Synuclein gene duplication is present in sporadic Parkinson disease</article-title><source>Neurology</source><volume>70</volume><issue>1</issue><year>2008</year><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">17625105</pub-id>
</element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Ulusoy</surname><given-names>A.</given-names></name><name><surname>Febbraro</surname><given-names>F.</given-names></name><name><surname>Jensen</surname><given-names>P.H.</given-names></name><name><surname>Kirik</surname><given-names>D.</given-names></name><name><surname>Romero-Ramos</surname><given-names>M.</given-names></name></person-group><article-title>Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology</article-title><source>Eur. J. Neurosci.</source><volume>32</volume><issue>3</issue><year>2010</year><fpage>409</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">20704592</pub-id>
</element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Emmanouilidou</surname><given-names>E.</given-names></name><name><surname>Papagiannakis</surname><given-names>N.</given-names></name><name><surname>Kouloulia</surname><given-names>S.</given-names></name><name><surname>Galaziou</surname><given-names>A.</given-names></name><name><surname>Antonellou</surname><given-names>R.</given-names></name><name><surname>Papadimitriou</surname><given-names>D.</given-names></name><name><surname>Athanasiadou</surname><given-names>A.</given-names></name><name><surname>Bozi</surname><given-names>M.</given-names></name><name><surname>Koros</surname><given-names>C.</given-names></name><name><surname>Maniati</surname><given-names>M.</given-names></name><name><surname>Vekrellis</surname><given-names>K.</given-names></name><name><surname>Ioannou</surname><given-names>P.C.</given-names></name><name><surname>Stefanis</surname><given-names>L.</given-names></name></person-group><article-title>Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease</article-title><source>Parkinsonism Relat. Disorders</source><volume>73</volume><year>2020</year><fpage>35</fpage><lpage>40</lpage></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Mammadova</surname><given-names>N.</given-names></name><name><surname>Baron</surname><given-names>T.</given-names></name><name><surname>Verchere</surname><given-names>J.</given-names></name><name><surname>Greenlee</surname><given-names>J.J.</given-names></name><name><surname>Greenlee</surname><given-names>M.H.W.</given-names></name></person-group><article-title>Retina as a model to study in vivo transmission of alpha-synuclein in the A53T mouse model of Parkinson's disease</article-title><source>Methods Mol. Biol.</source><volume>2224</volume><year>2021</year><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">33606207</pub-id>
</element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Bezard</surname><given-names>E.</given-names></name><name><surname>Gross</surname><given-names>C.E.</given-names></name><name><surname>Brotchie</surname><given-names>J.M.</given-names></name></person-group><article-title>Presymptomatic compensation in Parkinson's disease is not dopamine-mediated</article-title><source>Trends Neurosci.</source><volume>26</volume><issue>4</issue><year>2003</year><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">12689773</pub-id>
</element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>L.C.</given-names></name><name><surname>Di Giovanni</surname><given-names>G.</given-names></name><name><surname>Galati</surname><given-names>S.</given-names></name></person-group><article-title>Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms</article-title><source>J. Neurosci. Methods</source><volume>308</volume><year>2018</year><fpage>205</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">30107207</pub-id>
</element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>M.E.</given-names></name><name><surname>Toni</surname><given-names>I.</given-names></name><name><surname>Kessels</surname><given-names>R.P.C.</given-names></name><name><surname>Bloem</surname><given-names>B.R.</given-names></name><name><surname>Helmich</surname><given-names>R.C.</given-names></name></person-group><article-title>Clinical severity in Parkinson's disease is determined by decline in cortical compensation</article-title><source>Brain</source><volume>147</volume><issue>3</issue><year>2024</year><fpage>871</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">37757883</pub-id>
</element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>B.O.</given-names></name><name><surname>Batzu</surname><given-names>L.</given-names></name><name><surname>Ruiz</surname><given-names>P.J.G.</given-names></name><name><surname>Tulba</surname><given-names>D.</given-names></name><name><surname>Moro</surname><given-names>E.</given-names></name><name><surname>Santens</surname><given-names>P.</given-names></name></person-group><article-title>Neuroplasticity in Parkinson's disease</article-title><source>J. Neural. Transm.</source><volume>131</volume><issue>11</issue><year>2024</year><fpage>1329</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">39102007</pub-id>
</element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Passaretti</surname><given-names>M.</given-names></name><name><surname>Cilia</surname><given-names>R.</given-names></name><name><surname>Rinaldo</surname><given-names>S.</given-names></name><name><surname>Rossi Sebastiano</surname><given-names>D.</given-names></name><name><surname>Orunesu</surname><given-names>E.</given-names></name><name><surname>Devigili</surname><given-names>G.</given-names></name><name><surname>Braccia</surname><given-names>A.</given-names></name><name><surname>Paparella</surname><given-names>G.</given-names></name><name><surname>De Riggi</surname><given-names>M.</given-names></name><name><surname>van Eimeren</surname><given-names>T.</given-names></name><name><surname>Strafella</surname><given-names>A.P.</given-names></name><name><surname>Lanteri</surname><given-names>P.</given-names></name><name><surname>Berardelli</surname><given-names>A.</given-names></name><name><surname>Bologna</surname><given-names>M.</given-names></name><name><surname>Eleopra</surname><given-names>R.</given-names></name></person-group><article-title>Neurophysiological markers of motor compensatory mechanisms in early Parkinson's disease</article-title><source>Brain</source><volume>147</volume><issue>11</issue><year>2024</year><fpage>3714</fpage><lpage>3726</lpage><pub-id pub-id-type="pmid">39189320</pub-id>
</element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Lerche</surname><given-names>S.</given-names></name><name><surname>Wurster</surname><given-names>I.</given-names></name><name><surname>Roeben</surname><given-names>B.</given-names></name><name><surname>Zimmermann</surname><given-names>M.</given-names></name><name><surname>Riebenbauer</surname><given-names>B.</given-names></name><name><surname>Deuschle</surname><given-names>C.</given-names></name><name><surname>Hauser</surname><given-names>A.K.</given-names></name><name><surname>Schulte</surname><given-names>C.</given-names></name><name><surname>Berg</surname><given-names>D.</given-names></name><name><surname>Maetzler</surname><given-names>W.</given-names></name><name><surname>Waniek</surname><given-names>K.</given-names></name><name><surname>Lachmann</surname><given-names>I.</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I.</given-names></name><name><surname>Gasser</surname><given-names>T.</given-names></name><name><surname>Brockmann</surname><given-names>K.</given-names></name></person-group><article-title>Parkinson's disease: glucocerebrosidase 1 mutation severity is associated with CSF alpha-synuclein profiles</article-title><source>Mov. Disord.</source><volume>35</volume><issue>3</issue><year>2020</year><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">31670439</pub-id>
</element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Ledonne</surname><given-names>A.</given-names></name><name><surname>Massaro Cenere</surname><given-names>M.</given-names></name><name><surname>Paldino</surname><given-names>E.</given-names></name><name><surname>D'Angelo</surname><given-names>V.</given-names></name><name><surname>D'Addario</surname><given-names>S.L.</given-names></name><name><surname>Casadei</surname><given-names>N.</given-names></name><name><surname>Nobili</surname><given-names>A.</given-names></name><name><surname>Berretta</surname><given-names>N.</given-names></name><name><surname>Fusco</surname><given-names>F.R.</given-names></name><name><surname>Ventura</surname><given-names>R.</given-names></name><name><surname>Sancesario</surname><given-names>G.</given-names></name><name><surname>Guatteo</surname><given-names>E.</given-names></name><name><surname>Mercuri</surname><given-names>N.B.</given-names></name></person-group><article-title>Morpho-functional changes of nigral dopamine neurons in an alpha-synuclein model of Parkinson's disease</article-title><source>Mov. Disord.</source><volume>38</volume><issue>2</issue><year>2023</year><fpage>256</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">36350188</pub-id>
</element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Farzadfard</surname><given-names>A.</given-names></name><name><surname>Pedersen</surname><given-names>J.N.</given-names></name><name><surname>Meisl</surname><given-names>G.</given-names></name><name><surname>Somavarapu</surname><given-names>A.K.</given-names></name><name><surname>Alam</surname><given-names>P.</given-names></name><name><surname>Goksoyr</surname><given-names>L.</given-names></name><name><surname>Nielsen</surname><given-names>M.A.</given-names></name><name><surname>Sander</surname><given-names>A.F.</given-names></name><name><surname>Knowles</surname><given-names>T.P.J.</given-names></name><name><surname>Pedersen</surname><given-names>J.S.</given-names></name><name><surname>Otzen</surname><given-names>D.E.</given-names></name></person-group><article-title>The C-terminal tail of alpha-synuclein protects against aggregate replication but is critical for oligomerization</article-title><source>Commun. Biol.</source><volume>5</volume><issue>1</issue><year>2022</year><fpage>123</fpage><pub-id pub-id-type="pmid">35145226</pub-id>
</element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>K.C.</given-names></name><name><surname>Kehm</surname><given-names>V.</given-names></name><name><surname>Carroll</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>O'Brien</surname><given-names>P.</given-names></name><name><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name><surname>Lee</surname><given-names>V.M.</given-names></name></person-group><article-title>Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice</article-title><source>Science</source><volume>338</volume><issue>6109</issue><year>2012</year><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">23161999</pub-id>
</element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>L.</given-names></name><name><surname>Marano</surname><given-names>M.M.</given-names></name><name><surname>Tandon</surname><given-names>A.</given-names></name></person-group><article-title>Import and export of misfolded alpha-synuclein</article-title><source>Front. Neurosci.</source><volume>12</volume><year>2018</year><fpage>344</fpage><pub-id pub-id-type="pmid">29875627</pub-id>
</element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>H.</given-names></name><name><surname>Buckley</surname><given-names>J.A.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Fox</surname><given-names>T.H.</given-names><suffix>3rd</suffix></name><name><surname>Meares</surname><given-names>G.P.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Harms</surname><given-names>A.S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Standaert</surname><given-names>D.G.</given-names></name><name><surname>Benveniste</surname><given-names>E.N.</given-names></name></person-group><article-title>Inhibition of the JAK/STAT pathway protects against alpha-synuclein-induced neuroinflammation and dopaminergic neurodegeneration</article-title><source>J. Neurosci.</source><volume>36</volume><issue>18</issue><year>2016</year><fpage>5144</fpage><lpage>5159</lpage><pub-id pub-id-type="pmid">27147665</pub-id>
</element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>van der Wateren</surname><given-names>I.M.</given-names></name><name><surname>Knowles</surname><given-names>T.P.J.</given-names></name><name><surname>Buell</surname><given-names>A.K.</given-names></name><name><surname>Dobson</surname><given-names>C.M.</given-names></name><name><surname>Galvagnion</surname><given-names>C.</given-names></name></person-group><article-title>C-terminal truncation of alpha-synuclein promotes amyloid fibril amplification at physiological pH</article-title><source>Chem. Sci.</source><volume>9</volume><issue>25</issue><year>2018</year><fpage>5506</fpage><lpage>5516</lpage><pub-id pub-id-type="pmid">30061982</pub-id>
</element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Nemani</surname><given-names>V.M.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Berge</surname><given-names>V.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Onoa</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>M.K.</given-names></name><name><surname>Chaudhry</surname><given-names>F.A.</given-names></name><name><surname>Nicoll</surname><given-names>R.A.</given-names></name><name><surname>Edwards</surname><given-names>R.H.</given-names></name></person-group><article-title>Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis</article-title><source>Neuron</source><volume>65</volume><issue>1</issue><year>2010</year><fpage>66</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">20152114</pub-id>
</element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Ganjam</surname><given-names>G.K.</given-names></name><name><surname>Bolte</surname><given-names>K.</given-names></name><name><surname>Matschke</surname><given-names>L.A.</given-names></name><name><surname>Neitemeier</surname><given-names>S.</given-names></name><name><surname>Dolga</surname><given-names>A.M.</given-names></name><name><surname>Hollerhage</surname><given-names>M.</given-names></name><name><surname>Hoglinger</surname><given-names>G.U.</given-names></name><name><surname>Adamczyk</surname><given-names>A.</given-names></name><name><surname>Decher</surname><given-names>N.</given-names></name><name><surname>Oertel</surname><given-names>W.H.</given-names></name><name><surname>Culmsee</surname><given-names>C.</given-names></name></person-group><article-title>Mitochondrial damage by alpha-synuclein causes cell death in human dopaminergic neurons</article-title><source>Cell Death Dis.</source><volume>10</volume><issue>11</issue><year>2019</year><fpage>865</fpage><pub-id pub-id-type="pmid">31727879</pub-id>
</element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Gaugler</surname><given-names>M.N.</given-names></name><name><surname>Genc</surname><given-names>O.</given-names></name><name><surname>Bobela</surname><given-names>W.</given-names></name><name><surname>Mohanna</surname><given-names>S.</given-names></name><name><surname>Ardah</surname><given-names>M.T.</given-names></name><name><surname>El-Agnaf</surname><given-names>O.M.</given-names></name><name><surname>Cantoni</surname><given-names>M.</given-names></name><name><surname>Bensadoun</surname><given-names>J.C.</given-names></name><name><surname>Schneggenburger</surname><given-names>R.</given-names></name><name><surname>Knott</surname><given-names>G.W.</given-names></name><name><surname>Aebischer</surname><given-names>P.</given-names></name><name><surname>Schneider</surname><given-names>B.L.</given-names></name></person-group><article-title>Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity</article-title><source>Acta Neuropathol.</source><volume>123</volume><issue>5</issue><year>2012</year><fpage>653</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">22361813</pub-id>
</element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Kweon</surname><given-names>D.H.</given-names></name><name><surname>Kong</surname><given-names>B.</given-names></name><name><surname>Shin</surname><given-names>Y.K.</given-names></name></person-group><article-title>Search for a minimal machinery for Ca(2+)-triggered millisecond neuroexocytosis</article-title><source>Neuroscience</source><volume>420</volume><year>2019</year><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30056116</pub-id>
</element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Bellucci</surname><given-names>A.</given-names></name><name><surname>Navarria</surname><given-names>L.</given-names></name><name><surname>Zaltieri</surname><given-names>M.</given-names></name><name><surname>Falarti</surname><given-names>E.</given-names></name><name><surname>Bodei</surname><given-names>S.</given-names></name><name><surname>Sigala</surname><given-names>S.</given-names></name><name><surname>Battistin</surname><given-names>L.</given-names></name><name><surname>Spillantini</surname><given-names>M.</given-names></name><name><surname>Missale</surname><given-names>C.</given-names></name><name><surname>Spano</surname><given-names>P.</given-names></name></person-group><article-title>Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease</article-title><source>J. Neurochem.</source><volume>116</volume><issue>4</issue><year>2011</year><fpage>588</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">21166675</pub-id>
</element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Colla</surname><given-names>E.</given-names></name><name><surname>Coune</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pletnikova</surname><given-names>O.</given-names></name><name><surname>Troncoso</surname><given-names>J.C.</given-names></name><name><surname>Iwatsubo</surname><given-names>T.</given-names></name><name><surname>Schneider</surname><given-names>B.L.</given-names></name><name><surname>Lee</surname><given-names>M.K.</given-names></name></person-group><article-title>Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo</article-title><source>J. Neurosci.</source><volume>32</volume><issue>10</issue><year>2012</year><fpage>3306</fpage><lpage>3320</lpage><pub-id pub-id-type="pmid">22399753</pub-id>
</element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>M.F.</given-names></name><name><surname>Collier</surname><given-names>T.J.</given-names></name><name><surname>Patterson</surname><given-names>J.R.</given-names></name><name><surname>Kemp</surname><given-names>C.J.</given-names></name><name><surname>Luk</surname><given-names>K.C.</given-names></name><name><surname>Tansey</surname><given-names>M.G.</given-names></name><name><surname>Paumier</surname><given-names>K.L.</given-names></name><name><surname>Kanaan</surname><given-names>N.M.</given-names></name><name><surname>Fischer</surname><given-names>D.L.</given-names></name><name><surname>Polinski</surname><given-names>N.K.</given-names></name><name><surname>Barth</surname><given-names>O.L.</given-names></name><name><surname>Howe</surname><given-names>J.W.</given-names></name><name><surname>Vaikath</surname><given-names>N.N.</given-names></name><name><surname>Majbour</surname><given-names>N.K.</given-names></name><name><surname>El-Agnaf</surname><given-names>O.M.A.</given-names></name><name><surname>Sortwell</surname><given-names>C.E.</given-names></name></person-group><article-title>Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration</article-title><source>J. Neuroinflammation</source><volume>15</volume><issue>1</issue><year>2018</year><fpage>129</fpage><pub-id pub-id-type="pmid">29716614</pub-id>
</element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Iba</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Sallin</surname><given-names>M.</given-names></name><name><surname>Kwon</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name><name><surname>Overk</surname><given-names>C.</given-names></name><name><surname>Rissman</surname><given-names>R.A.</given-names></name><name><surname>Sen</surname><given-names>R.</given-names></name><name><surname>Sen</surname><given-names>J.M.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Neuroinflammation is associated with infiltration of T cells in Lewy body disease and alpha-synuclein transgenic models</article-title><source>J. Neuroinflammation</source><volume>17</volume><issue>1</issue><year>2020</year><fpage>214</fpage><pub-id pub-id-type="pmid">32680537</pub-id>
</element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Varkey</surname><given-names>J.</given-names></name><name><surname>Lou</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>J.K.</given-names></name><name><surname>Diao</surname><given-names>J.</given-names></name><name><surname>Langen</surname><given-names>R.</given-names></name><name><surname>Shin</surname><given-names>Y.K.</given-names></name></person-group><article-title>Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding</article-title><source>Biochemistry</source><volume>53</volume><issue>24</issue><year>2014</year><fpage>3889</fpage><lpage>3896</lpage><pub-id pub-id-type="pmid">24884175</pub-id>
</element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>P.</given-names></name><name><surname>Jurgens-Wemheuer</surname><given-names>W.</given-names></name><name><surname>Uriarte Huarte</surname><given-names>O.</given-names></name><name><surname>Michelucci</surname><given-names>A.</given-names></name><name><surname>Masuch</surname><given-names>A.</given-names></name><name><surname>Brioschi</surname><given-names>S.</given-names></name><name><surname>Weihofen</surname><given-names>A.</given-names></name><name><surname>Koncina</surname><given-names>E.</given-names></name><name><surname>Coowar</surname><given-names>D.</given-names></name><name><surname>Heurtaux</surname><given-names>T.</given-names></name><name><surname>Glaab</surname><given-names>E.</given-names></name><name><surname>Balling</surname><given-names>R.</given-names></name><name><surname>Sousa</surname><given-names>C.</given-names></name><name><surname>Kaoma</surname><given-names>T.</given-names></name><name><surname>Nicot</surname><given-names>N.</given-names></name><name><surname>Pfander</surname><given-names>T.</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W.</given-names></name><name><surname>Allouche</surname><given-names>A.</given-names></name><name><surname>Fischer</surname><given-names>N.</given-names></name><name><surname>Biber</surname><given-names>K.</given-names></name><name><surname>Kleine-Borgmann</surname><given-names>F.</given-names></name><name><surname>Mittelbronn</surname><given-names>M.</given-names></name><name><surname>Ostaszewski</surname><given-names>M.</given-names></name><name><surname>Schmit</surname><given-names>K.J.</given-names></name><name><surname>Buttini</surname><given-names>M.</given-names></name></person-group><article-title>Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease</article-title><source>Glia</source><volume>70</volume><issue>5</issue><year>2022</year><fpage>935</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">35092321</pub-id>
</element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Izco</surname><given-names>M.</given-names></name><name><surname>Blesa</surname><given-names>J.</given-names></name><name><surname>Verona</surname><given-names>G.</given-names></name><name><surname>Cooper</surname><given-names>J.M.</given-names></name><name><surname>Alvarez-Erviti</surname><given-names>L.</given-names></name></person-group><article-title>Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson's disease</article-title><source>Neurosci. Res.</source><volume>170</volume><year>2021</year><fpage>330</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">33316306</pub-id>
</element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Wan</surname><given-names>F.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Kou</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Xiong</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name></person-group><article-title>Targeting microglial alpha-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome Axis in Parkinson's disease</article-title><source>Front. Immunol.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">719807</object-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Dijkstra</surname><given-names>A.A.</given-names></name><name><surname>Ingrassia</surname><given-names>A.</given-names></name><name><surname>de Menezes</surname><given-names>R.X.</given-names></name><name><surname>van Kesteren</surname><given-names>R.E.</given-names></name><name><surname>Rozemuller</surname><given-names>A.J.</given-names></name><name><surname>Heutink</surname><given-names>P.</given-names></name><name><surname>van de Berg</surname><given-names>W.D.</given-names></name></person-group><article-title>Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson's disease</article-title><source>PLoS One</source><volume>10</volume><issue>6</issue><year>2015</year><object-id pub-id-type="publisher-id">e0128651</object-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Ginns</surname><given-names>E.I.</given-names></name><name><surname>Mak</surname><given-names>S.K.</given-names></name><name><surname>Ko</surname><given-names>N.</given-names></name><name><surname>Karlgren</surname><given-names>J.</given-names></name><name><surname>Akbarian</surname><given-names>S.</given-names></name><name><surname>Chou</surname><given-names>V.P.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Lim</surname><given-names>A.</given-names></name><name><surname>Samuelsson</surname><given-names>S.</given-names></name><name><surname>LaMarca</surname><given-names>M.L.</given-names></name><name><surname>Vazquez-DeRose</surname><given-names>J.</given-names></name><name><surname>Manning-Bog</surname><given-names>A.B.</given-names></name></person-group><article-title>Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction</article-title><source>Mol. Genet. Metabol.</source><volume>111</volume><issue>2</issue><year>2014</year><fpage>152</fpage><lpage>162</lpage></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>A.S.</given-names></name><name><surname>Delic</surname><given-names>V.</given-names></name><name><surname>Thome</surname><given-names>A.D.</given-names></name><name><surname>Bryant</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chandra</surname><given-names>S.</given-names></name><name><surname>Jurkuvenaite</surname><given-names>A.</given-names></name><name><surname>West</surname><given-names>A.B.</given-names></name></person-group><article-title>alpha-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration</article-title><source>Acta Neuropathol Commun</source><volume>5</volume><issue>1</issue><year>2017</year><fpage>85</fpage><pub-id pub-id-type="pmid">29162163</pub-id>
</element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Bido</surname><given-names>S.</given-names></name><name><surname>Muggeo</surname><given-names>S.</given-names></name><name><surname>Massimino</surname><given-names>L.</given-names></name><name><surname>Marzi</surname><given-names>M.J.</given-names></name><name><surname>Giannelli</surname><given-names>S.G.</given-names></name><name><surname>Melacini</surname><given-names>E.</given-names></name><name><surname>Nannoni</surname><given-names>M.</given-names></name><name><surname>Gambare</surname><given-names>D.</given-names></name><name><surname>Bellini</surname><given-names>E.</given-names></name><name><surname>Ordazzo</surname><given-names>G.</given-names></name><name><surname>Rossi</surname><given-names>G.</given-names></name><name><surname>Maffezzini</surname><given-names>C.</given-names></name><name><surname>Iannelli</surname><given-names>A.</given-names></name><name><surname>Luoni</surname><given-names>M.</given-names></name><name><surname>Bacigaluppi</surname><given-names>M.</given-names></name><name><surname>Gregori</surname><given-names>S.</given-names></name><name><surname>Nicassio</surname><given-names>F.</given-names></name><name><surname>Broccoli</surname><given-names>V.</given-names></name></person-group><article-title>Microglia-specific overexpression of alpha-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity</article-title><source>Nat. Commun.</source><volume>12</volume><issue>1</issue><year>2021</year><fpage>6237</fpage><pub-id pub-id-type="pmid">34716339</pub-id>
</element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>I.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Seegobin</surname><given-names>S.P.</given-names></name><name><surname>Pruvost</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Purtell</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Yue</surname><given-names>Z.</given-names></name></person-group><article-title>Microglia clear neuron-released alpha-synuclein via selective autophagy and prevent neurodegeneration</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>1386</fpage><pub-id pub-id-type="pmid">32170061</pub-id>
</element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Gorecki</surname><given-names>A.M.</given-names></name><name><surname>Anyaegbu</surname><given-names>C.C.</given-names></name><name><surname>Anderton</surname><given-names>R.S.</given-names></name></person-group><article-title>TLR2 and TLR4 in Parkinson's disease pathogenesis: the environment takes a toll on the gut</article-title><source>Transl. Neurodegener.</source><volume>10</volume><issue>1</issue><year>2021</year><fpage>47</fpage><pub-id pub-id-type="pmid">34814947</pub-id>
</element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Bonam</surname><given-names>S.R.</given-names></name><name><surname>Tranchant</surname><given-names>C.</given-names></name><name><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>Autophagy-lysosomal pathway as potential therapeutic target in Parkinson's disease</article-title><source>Cells</source><volume>10</volume><issue>12</issue><year>2021</year></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>H.J.</given-names></name><name><surname>Hartfield</surname><given-names>E.M.</given-names></name><name><surname>Christian</surname><given-names>H.C.</given-names></name><name><surname>Emmanoulidou</surname><given-names>E.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Booth</surname><given-names>H.</given-names></name><name><surname>Bogetofte</surname><given-names>H.</given-names></name><name><surname>Lang</surname><given-names>C.</given-names></name><name><surname>Ryan</surname><given-names>B.J.</given-names></name><name><surname>Sardi</surname><given-names>S.P.</given-names></name><name><surname>Badger</surname><given-names>J.</given-names></name><name><surname>Vowles</surname><given-names>J.</given-names></name><name><surname>Evetts</surname><given-names>S.</given-names></name><name><surname>Tofaris</surname><given-names>G.K.</given-names></name><name><surname>Vekrellis</surname><given-names>K.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Hu</surname><given-names>M.T.</given-names></name><name><surname>James</surname><given-names>W.</given-names></name><name><surname>Cowley</surname><given-names>S.A.</given-names></name><name><surname>Wade-Martins</surname><given-names>R.</given-names></name></person-group><article-title>ER stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons</article-title><source>Stem Cell Rep.</source><volume>6</volume><issue>3</issue><year>2016</year><fpage>342</fpage><lpage>356</lpage></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>A.</given-names></name><name><surname>Spinelli</surname><given-names>C.C.</given-names></name><name><surname>Martucciello</surname><given-names>S.</given-names></name><name><surname>Nori</surname><given-names>S.L.</given-names></name><name><surname>Capunzo</surname><given-names>M.</given-names></name><name><surname>Puca</surname><given-names>A.A.</given-names></name><name><surname>Ciaglia</surname><given-names>E.</given-names></name></person-group><article-title>Innate immunity and cellular senescence: the good and the bad in the developmental and aged brain</article-title><source>J. Leukoc. Biol.</source><volume>103</volume><issue>3</issue><year>2018</year><fpage>509</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">29389023</pub-id>
</element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>H.Y.</given-names></name><name><surname>Yuan</surname><given-names>B.S.</given-names></name><name><surname>Hou</surname><given-names>X.O.</given-names></name><name><surname>Zhang</surname><given-names>X.J.</given-names></name><name><surname>Pei</surname><given-names>C.S.</given-names></name><name><surname>Ma</surname><given-names>Y.T.</given-names></name><name><surname>Yang</surname><given-names>Y.P.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>Z.H.</given-names></name><name><surname>Liu</surname><given-names>C.F.</given-names></name><name><surname>Hu</surname><given-names>L.F.</given-names></name></person-group><article-title>alpha-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease</article-title><source>Aging Cell</source><volume>20</volume><issue>12</issue><year>2021</year><object-id pub-id-type="publisher-id">e13522</object-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>M.N.</given-names></name><name><surname>Christiansen</surname><given-names>J.R.</given-names></name><name><surname>Petersen</surname><given-names>S.V.</given-names></name><name><surname>Jensen</surname><given-names>P.H.</given-names></name><name><surname>Paslawski</surname><given-names>W.</given-names></name><name><surname>Romero-Ramos</surname><given-names>M.</given-names></name><name><surname>Sanchez-Guajardo</surname><given-names>V.</given-names></name></person-group><article-title>CD4 T cells react to local increase of alpha-synuclein in a pathology-associated variant-dependent manner and modify brain microglia in absence of brain pathology</article-title><source>Heliyon</source><volume>4</volume><issue>1</issue><year>2018</year><object-id pub-id-type="publisher-id">e00513</object-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>A.S.</given-names></name><name><surname>Thome</surname><given-names>A.D.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Schonhoff</surname><given-names>A.M.</given-names></name><name><surname>Williams</surname><given-names>G.P.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>H.</given-names></name><name><surname>Benveniste</surname><given-names>E.N.</given-names></name><name><surname>Standaert</surname><given-names>D.G.</given-names></name></person-group><article-title>Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease</article-title><source>Exp. Neurol.</source><volume>300</volume><year>2018</year><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">29155051</pub-id>
</element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Sulzer</surname><given-names>D.</given-names></name><name><surname>Alcalay</surname><given-names>R.N.</given-names></name><name><surname>Garretti</surname><given-names>F.</given-names></name><name><surname>Cote</surname><given-names>L.</given-names></name><name><surname>Kanter</surname><given-names>E.</given-names></name><name><surname>Agin-Liebes</surname><given-names>J.</given-names></name><name><surname>Liong</surname><given-names>C.</given-names></name><name><surname>McMurtrey</surname><given-names>C.</given-names></name><name><surname>Hildebrand</surname><given-names>W.H.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name><name><surname>Oseroff</surname><given-names>C.</given-names></name><name><surname>Pham</surname><given-names>J.</given-names></name><name><surname>Sidney</surname><given-names>J.</given-names></name><name><surname>Dillon</surname><given-names>M.B.</given-names></name><name><surname>Carpenter</surname><given-names>C.</given-names></name><name><surname>Weiskopf</surname><given-names>D.</given-names></name><name><surname>Phillips</surname><given-names>E.</given-names></name><name><surname>Mallal</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>B.</given-names></name><name><surname>Frazier</surname><given-names>A.</given-names></name><name><surname>Lindestam Arlehamn</surname><given-names>C.S.</given-names></name><name><surname>Sette</surname><given-names>A.</given-names></name></person-group><article-title>T cells from patients with Parkinson's disease recognize alpha-synuclein peptides</article-title><source>Nature</source><volume>546</volume><issue>7660</issue><year>2017</year><fpage>656</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">28636593</pub-id>
</element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Kloepper</surname><given-names>T.H.</given-names></name><name><surname>Kienle</surname><given-names>C.N.</given-names></name><name><surname>Fasshauer</surname><given-names>D.</given-names></name></person-group><article-title>An elaborate classification of SNARE proteins sheds light on the conservation of the eukaryotic endomembrane system</article-title><source>Mol. Biol. Cell</source><volume>18</volume><issue>9</issue><year>2007</year><fpage>3463</fpage><lpage>3471</lpage><pub-id pub-id-type="pmid">17596510</pub-id>
</element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>R.B.</given-names></name><name><surname>Fasshauer</surname><given-names>D.</given-names></name><name><surname>Jahn</surname><given-names>R.</given-names></name><name><surname>Brunger</surname><given-names>A.T.</given-names></name></person-group><article-title>Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution</article-title><source>Nature</source><volume>395</volume><issue>6700</issue><year>1998</year><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">9759724</pub-id>
</element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Stow</surname><given-names>J.L.</given-names></name><name><surname>Manderson</surname><given-names>A.P.</given-names></name><name><surname>Murray</surname><given-names>R.Z.</given-names></name></person-group><article-title>SNAREing immunity: the role of SNAREs in the immune system</article-title><source>Nat. Rev. Immunol.</source><volume>6</volume><issue>12</issue><year>2006</year><fpage>919</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">17124513</pub-id>
</element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>R.</given-names></name><name><surname>Scheller</surname><given-names>R.H.</given-names></name></person-group><article-title>SNAREs--engines for membrane fusion</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>7</volume><issue>9</issue><year>2006</year><fpage>631</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">16912714</pub-id>
</element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Snead</surname><given-names>D.</given-names></name><name><surname>Eliezer</surname><given-names>D.</given-names></name></person-group><article-title>Alpha-synuclein function and dysfunction on cellular membranes</article-title><source>Exp Neurobiol</source><volume>23</volume><issue>4</issue><year>2014</year><fpage>292</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">25548530</pub-id>
</element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>G.</given-names></name><name><surname>Shin</surname><given-names>Y.K.</given-names></name><name><surname>Lee</surname><given-names>N.K.</given-names></name></person-group><article-title>The role of alpha-synuclein in SNARE-mediated synaptic vesicle fusion</article-title><source>J. Mol. Biol.</source><volume>435</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">167775</object-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Hawk</surname><given-names>B.J.</given-names></name><name><surname>Shin</surname><given-names>Y.K.</given-names></name></person-group><article-title>alpha-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking</article-title><source>Biochem. J.</source><volume>474</volume><issue>12</issue><year>2017</year><fpage>2039</fpage><lpage>2049</lpage><pub-id pub-id-type="pmid">28495859</pub-id>
</element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>T.</given-names></name><name><surname>Bendor</surname><given-names>J.</given-names></name><name><surname>Toupin</surname><given-names>C.</given-names></name><name><surname>Thorn</surname><given-names>K.</given-names></name><name><surname>Edwards</surname><given-names>R.H.</given-names></name></person-group><article-title>alpha-Synuclein promotes dilation of the exocytotic fusion pore</article-title><source>Nat. Neurosci.</source><volume>20</volume><issue>5</issue><year>2017</year><fpage>681</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">28288128</pub-id>
</element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>Y.</given-names></name><name><surname>Tsujimura</surname><given-names>A.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Expression of alpha-synuclein is regulated in a neuronal cell type-dependent manner</article-title><source>Anat. Sci. Int.</source><volume>94</volume><issue>1</issue><year>2019</year><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">30362073</pub-id>
</element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>DeWitt</surname><given-names>D.C.</given-names></name><name><surname>Rhoades</surname><given-names>E.</given-names></name></person-group><article-title>alpha-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers</article-title><source>Biochemistry</source><volume>52</volume><issue>14</issue><year>2013</year><fpage>2385</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">23528131</pub-id>
</element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>A.R.</given-names></name><name><surname>Sachs</surname><given-names>J.N.</given-names></name></person-group><article-title>Alpha-synuclein reduces tension and increases undulations in simulations of small unilamellar vesicles</article-title><source>Biophys. J.</source><volume>108</volume><issue>8</issue><year>2015</year><fpage>1848</fpage><lpage>1851</lpage><pub-id pub-id-type="pmid">25902424</pub-id>
</element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>D.</given-names></name><name><surname>Sakurai</surname><given-names>C.</given-names></name><name><surname>Morita</surname><given-names>M.</given-names></name><name><surname>Tsunematsu</surname><given-names>M.</given-names></name><name><surname>Hori</surname><given-names>N.</given-names></name><name><surname>Hatsuzawa</surname><given-names>K.</given-names></name></person-group><article-title>Syntaxin 11 regulates the stimulus-dependent transport of Toll-like receptor 4 to the plasma membrane by cooperating with SNAP-23 in macrophages</article-title><source>Mol. Biol. Cell</source><volume>30</volume><issue>9</issue><year>2019</year><fpage>1085</fpage><lpage>1097</lpage><pub-id pub-id-type="pmid">30811271</pub-id>
</element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Mechanisms of TLR4-mediated autophagy and nitroxidative stress</article-title><source>Front. Cell. Infect. Microbiol.</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">766590</object-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Celkan</surname><given-names>T.</given-names></name><name><surname>Nordenskjold</surname><given-names>M.</given-names></name><name><surname>Henter</surname><given-names>J.I.</given-names></name><name><surname>Fadeel</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>C.</given-names></name></person-group><article-title>Syntaxin-11 is expressed in primary human monocytes/macrophages and acts as a negative regulator of macrophage engulfment of apoptotic cells and IgG-opsonized target cells</article-title><source>Br. J. Haematol.</source><volume>142</volume><issue>3</issue><year>2008</year><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">18547321</pub-id>
</element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>C.</given-names></name><name><surname>Itakura</surname><given-names>M.</given-names></name><name><surname>Kinoshita</surname><given-names>D.</given-names></name><name><surname>Arai</surname><given-names>S.</given-names></name><name><surname>Hashimoto</surname><given-names>H.</given-names></name><name><surname>Wada</surname><given-names>I.</given-names></name><name><surname>Hatsuzawa</surname><given-names>K.</given-names></name></person-group><article-title>Phosphorylation of SNAP-23 at Ser95 causes a structural alteration and negatively regulates Fc receptor-mediated phagosome formation and maturation in macrophages</article-title><source>Mol. Biol. Cell</source><volume>29</volume><issue>13</issue><year>2018</year><fpage>1753</fpage><lpage>1762</lpage><pub-id pub-id-type="pmid">29771640</pub-id>
</element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Itakura</surname><given-names>E.</given-names></name><name><surname>Kishi-Itakura</surname><given-names>C.</given-names></name><name><surname>Mizushima</surname><given-names>N.</given-names></name></person-group><article-title>The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes</article-title><source>Cell</source><volume>151</volume><issue>6</issue><year>2012</year><fpage>1256</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">23217709</pub-id>
</element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Grakoui</surname><given-names>A.</given-names></name><name><surname>Bromley</surname><given-names>S.K.</given-names></name><name><surname>Sumen</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>M.M.</given-names></name><name><surname>Shaw</surname><given-names>A.S.</given-names></name><name><surname>Allen</surname><given-names>P.M.</given-names></name><name><surname>Dustin</surname><given-names>M.L.</given-names></name></person-group><article-title>The immunological synapse: a molecular machine controlling T cell activation</article-title><source>Science</source><volume>285</volume><issue>5425</issue><year>1999</year><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">10398592</pub-id>
</element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Dustin</surname><given-names>M.L.</given-names></name><name><surname>Choudhuri</surname><given-names>K.</given-names></name></person-group><article-title>Signaling and polarized communication across the T cell immunological synapse</article-title><source>Annu. Rev. Cell Dev. Biol.</source><volume>32</volume><year>2016</year><fpage>303</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">27501450</pub-id>
</element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Saez</surname><given-names>J.J.</given-names></name><name><surname>Dogniaux</surname><given-names>S.</given-names></name><name><surname>Shafaq-Zadah</surname><given-names>M.</given-names></name><name><surname>Johannes</surname><given-names>L.</given-names></name><name><surname>Hivroz</surname><given-names>C.</given-names></name><name><surname>Zucchetti</surname><given-names>A.E.</given-names></name></person-group><article-title>Retrograde and anterograde transport of lat-vesicles during the immunological synapse formation: defining the finely-tuned mechanism</article-title><source>Cells</source><volume>10</volume><issue>2</issue><year>2021</year></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>M.R.</given-names></name><name><surname>Pattu</surname><given-names>V.</given-names></name><name><surname>Halimani</surname><given-names>M.</given-names></name><name><surname>Maier-Peuschel</surname><given-names>M.</given-names></name><name><surname>Muller</surname><given-names>M.L.</given-names></name><name><surname>Becherer</surname><given-names>U.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name><name><surname>Hoth</surname><given-names>M.</given-names></name><name><surname>Tschernig</surname><given-names>T.</given-names></name><name><surname>Bryceson</surname><given-names>Y.T.</given-names></name><name><surname>Rettig</surname><given-names>J.</given-names></name></person-group><article-title>VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity</article-title><source>J. Cell Biol.</source><volume>210</volume><issue>1</issue><year>2015</year><fpage>135</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">26124288</pub-id>
</element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Spessott</surname><given-names>W.A.</given-names></name><name><surname>Sanmillan</surname><given-names>M.L.</given-names></name><name><surname>Kulkarni</surname><given-names>V.V.</given-names></name><name><surname>McCormick</surname><given-names>M.E.</given-names></name><name><surname>Giraudo</surname><given-names>C.G.</given-names></name></person-group><article-title>Syntaxin 4 mediates endosome recycling for lytic granule exocytosis in cytotoxic T-lymphocytes</article-title><source>Traffic</source><volume>18</volume><issue>7</issue><year>2017</year><fpage>442</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">28471021</pub-id>
</element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Matti</surname><given-names>U.</given-names></name><name><surname>Pattu</surname><given-names>V.</given-names></name><name><surname>Halimani</surname><given-names>M.</given-names></name><name><surname>Schirra</surname><given-names>C.</given-names></name><name><surname>Krause</surname><given-names>E.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Weins</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>H.F.</given-names></name><name><surname>Guzman</surname><given-names>R.</given-names></name><name><surname>Olausson</surname><given-names>J.</given-names></name><name><surname>Freichel</surname><given-names>M.</given-names></name><name><surname>Schmitz</surname><given-names>F.</given-names></name><name><surname>Pasche</surname><given-names>M.</given-names></name><name><surname>Becherer</surname><given-names>U.</given-names></name><name><surname>Bruns</surname><given-names>D.</given-names></name><name><surname>Rettig</surname><given-names>J.</given-names></name></person-group><article-title>Synaptobrevin2 is the v-SNARE required for cytotoxic T-lymphocyte lytic granule fusion</article-title><source>Nat. Commun.</source><volume>4</volume><year>2013</year><fpage>1439</fpage><pub-id pub-id-type="pmid">23385584</pub-id>
</element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>S.S.</given-names></name><name><surname>Friedmann</surname><given-names>K.S.</given-names></name><name><surname>Knorck</surname><given-names>A.</given-names></name><name><surname>Hoxha</surname><given-names>C.</given-names></name><name><surname>Leidinger</surname><given-names>P.</given-names></name><name><surname>Backes</surname><given-names>C.</given-names></name><name><surname>Meese</surname><given-names>E.</given-names></name><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Rettig</surname><given-names>J.</given-names></name><name><surname>Hoth</surname><given-names>M.</given-names></name><name><surname>Qu</surname><given-names>B.</given-names></name><name><surname>Schwarz</surname><given-names>E.C.</given-names></name></person-group><article-title>Syntaxin 8 is required for efficient lytic granule trafficking in cytotoxic T lymphocytes</article-title><source>Biochim. Biophys. Acta</source><volume>1863</volume><issue>7 Pt A</issue><year>2016</year><fpage>1653</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">27094127</pub-id>
</element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Schoppmeyer</surname><given-names>R.</given-names></name><name><surname>van Steen</surname><given-names>A.C.I.</given-names></name><name><surname>Kempers</surname><given-names>L.</given-names></name><name><surname>Timmerman</surname><given-names>A.L.</given-names></name><name><surname>Nolte</surname><given-names>M.A.</given-names></name><name><surname>Hombrink</surname><given-names>P.</given-names></name><name><surname>van Buul</surname><given-names>J.D.</given-names></name></person-group><article-title>The endothelial diapedesis synapse regulates transcellular migration of human T lymphocytes in a CX3CL1- and SNAP23-dependent manner</article-title><source>Cell Rep.</source><volume>38</volume><issue>3</issue><year>2022</year><object-id pub-id-type="publisher-id">110243</object-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Burre</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Tsetsenis</surname><given-names>T.</given-names></name><name><surname>Buchman</surname><given-names>V.</given-names></name><name><surname>Etherton</surname><given-names>M.R.</given-names></name><name><surname>Sudhof</surname><given-names>T.C.</given-names></name></person-group><article-title>Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro</article-title><source>Science</source><volume>329</volume><issue>5999</issue><year>2010</year><fpage>1663</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">20798282</pub-id>
</element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Darios</surname><given-names>F.</given-names></name><name><surname>Ruiperez</surname><given-names>V.</given-names></name><name><surname>Lopez</surname><given-names>I.</given-names></name><name><surname>Villanueva</surname><given-names>J.</given-names></name><name><surname>Gutierrez</surname><given-names>L.M.</given-names></name><name><surname>Davletov</surname><given-names>B.</given-names></name></person-group><article-title>Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis</article-title><source>EMBO Rep.</source><volume>11</volume><issue>7</issue><year>2010</year><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">20489724</pub-id>
</element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>J.</given-names></name><name><surname>Burre</surname><given-names>J.</given-names></name><name><surname>Vivona</surname><given-names>S.</given-names></name><name><surname>Cipriano</surname><given-names>D.J.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Kyoung</surname><given-names>M.</given-names></name><name><surname>Sudhof</surname><given-names>T.C.</given-names></name><name><surname>Brunger</surname><given-names>A.T.</given-names></name></person-group><article-title>Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2</article-title><source>Elife</source><volume>2</volume><year>2013</year><object-id pub-id-type="publisher-id">e00592</object-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>C.X.</given-names></name></person-group><article-title>SNARE proteins mediate alpha-synuclein secretion via multiple vesicular pathways</article-title><source>Mol. Neurobiol.</source><volume>59</volume><issue>1</issue><year>2022</year><fpage>405</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">34705229</pub-id>
</element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Hooshmand</surname><given-names>K.</given-names></name><name><surname>Halliday</surname><given-names>G.M.</given-names></name><name><surname>Pineda</surname><given-names>S.S.</given-names></name><name><surname>Sutherland</surname><given-names>G.T.</given-names></name><name><surname>Guennewig</surname><given-names>B.</given-names></name></person-group><article-title>Overlap between central and peripheral transcriptomes in Parkinson's disease but not alzheimer's disease</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><issue>9</issue><year>2022</year></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Thayanidhi</surname><given-names>N.</given-names></name><name><surname>Helm</surname><given-names>J.R.</given-names></name><name><surname>Nycz</surname><given-names>D.C.</given-names></name><name><surname>Bentley</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Hay</surname><given-names>J.C.</given-names></name></person-group><article-title>Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs</article-title><source>Mol. Biol. Cell</source><volume>21</volume><issue>11</issue><year>2010</year><fpage>1850</fpage><lpage>1863</lpage><pub-id pub-id-type="pmid">20392839</pub-id>
</element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>A.A.</given-names></name><name><surname>Gitler</surname><given-names>A.D.</given-names></name><name><surname>Cashikar</surname><given-names>A.</given-names></name><name><surname>Haynes</surname><given-names>C.M.</given-names></name><name><surname>Hill</surname><given-names>K.J.</given-names></name><name><surname>Bhullar</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Strathearn</surname><given-names>K.E.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Caldwell</surname><given-names>K.A.</given-names></name><name><surname>Caldwell</surname><given-names>G.A.</given-names></name><name><surname>Marsischky</surname><given-names>G.</given-names></name><name><surname>Kolodner</surname><given-names>R.D.</given-names></name><name><surname>Labaer</surname><given-names>J.</given-names></name><name><surname>Rochet</surname><given-names>J.C.</given-names></name><name><surname>Bonini</surname><given-names>N.M.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name></person-group><article-title>Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models</article-title><source>Science</source><volume>313</volume><issue>5785</issue><year>2006</year><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">16794039</pub-id>
</element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>B.K.</given-names></name><name><surname>Choi</surname><given-names>M.G.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Lai</surname><given-names>Y.</given-names></name><name><surname>Kweon</surname><given-names>D.H.</given-names></name><name><surname>Lee</surname><given-names>N.K.</given-names></name><name><surname>Shin</surname><given-names>Y.K.</given-names></name></person-group><article-title>Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume><issue>10</issue><year>2013</year><fpage>4087</fpage><lpage>4092</lpage><pub-id pub-id-type="pmid">23431141</pub-id>
</element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Agliardi</surname><given-names>C.</given-names></name><name><surname>Meloni</surname><given-names>M.</given-names></name><name><surname>Guerini</surname><given-names>F.R.</given-names></name><name><surname>Zanzottera</surname><given-names>M.</given-names></name><name><surname>Bolognesi</surname><given-names>E.</given-names></name><name><surname>Baglio</surname><given-names>F.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name></person-group><article-title>Oligomeric alpha-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease</article-title><source>Neurobiol. Dis.</source><volume>148</volume><year>2021</year><object-id pub-id-type="publisher-id">105185</object-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F.</given-names></name><name><surname>Burns</surname><given-names>K.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name></person-group><article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta</article-title><source>Mol. Cell</source><volume>10</volume><issue>2</issue><year>2002</year><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">12191486</pub-id>
</element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>J.S.</given-names></name><name><surname>Sohn</surname><given-names>D.H.</given-names></name></person-group><article-title>Damage-associated molecular patterns in inflammatory diseases</article-title><source>Immune Netw</source><volume>18</volume><issue>4</issue><year>2018</year><fpage>e27</fpage><pub-id pub-id-type="pmid">30181915</pub-id>
</element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name><name><surname>Peng</surname><given-names>S.</given-names></name></person-group><article-title>Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment</article-title><source>J. Neuroinflammation</source><volume>15</volume><issue>1</issue><year>2018</year><fpage>109</fpage><pub-id pub-id-type="pmid">29665808</pub-id>
</element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Codolo</surname><given-names>G.</given-names></name><name><surname>Plotegher</surname><given-names>N.</given-names></name><name><surname>Pozzobon</surname><given-names>T.</given-names></name><name><surname>Brucale</surname><given-names>M.</given-names></name><name><surname>Tessari</surname><given-names>I.</given-names></name><name><surname>Bubacco</surname><given-names>L.</given-names></name><name><surname>de Bernard</surname><given-names>M.</given-names></name></person-group><article-title>Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies</article-title><source>PLoS One</source><volume>8</volume><issue>1</issue><year>2013</year><object-id pub-id-type="publisher-id">e55375</object-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>M.Y.</given-names></name><name><surname>Lin</surname><given-names>Y.Y.</given-names></name><name><surname>Zhang</surname><given-names>B.J.</given-names></name><name><surname>Lu</surname><given-names>D.L.</given-names></name><name><surname>Lu</surname><given-names>Z.Q.</given-names></name><name><surname>Cai</surname><given-names>W.</given-names></name></person-group><article-title>Update of inflammasome activation in microglia/macrophage in aging and aging-related disease</article-title><source>CNS Neurosci. Ther.</source><volume>25</volume><issue>12</issue><year>2019</year><fpage>1299</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">31729181</pub-id>
</element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Heidari</surname><given-names>A.</given-names></name><name><surname>Yazdanpanah</surname><given-names>N.</given-names></name><name><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>The role of Toll-like receptors and neuroinflammation in Parkinson's disease</article-title><source>J. Neuroinflammation</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>135</fpage><pub-id pub-id-type="pmid">35668422</pub-id>
</element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Khairnar</surname><given-names>A.</given-names></name></person-group><article-title>Intranasal rotenone induces alpha-synuclein accumulation, neuroinflammation and dopaminergic neurodegeneration in middle-aged mice</article-title><source>Neurochem. Res.</source><volume>48</volume><issue>5</issue><year>2023</year><fpage>1543</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">36571663</pub-id>
</element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name><surname>Acosta</surname><given-names>J.C.</given-names></name><name><surname>Banito</surname><given-names>A.</given-names></name><name><surname>Wuestefeld</surname><given-names>T.</given-names></name><name><surname>Georgilis</surname><given-names>A.</given-names></name><name><surname>Janich</surname><given-names>P.</given-names></name><name><surname>Morton</surname><given-names>J.P.</given-names></name><name><surname>Athineos</surname><given-names>D.</given-names></name><name><surname>Kang</surname><given-names>T.W.</given-names></name><name><surname>Lasitschka</surname><given-names>F.</given-names></name><name><surname>Andrulis</surname><given-names>M.</given-names></name><name><surname>Pascual</surname><given-names>G.</given-names></name><name><surname>Morris</surname><given-names>K.J.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Dharmalingam</surname><given-names>G.</given-names></name><name><surname>Snijders</surname><given-names>A.P.</given-names></name><name><surname>Carroll</surname><given-names>T.</given-names></name><name><surname>Capper</surname><given-names>D.</given-names></name><name><surname>Pritchard</surname><given-names>C.</given-names></name><name><surname>Inman</surname><given-names>G.J.</given-names></name><name><surname>Longerich</surname><given-names>T.</given-names></name><name><surname>Sansom</surname><given-names>O.J.</given-names></name><name><surname>Benitah</surname><given-names>S.A.</given-names></name><name><surname>Zender</surname><given-names>L.</given-names></name><name><surname>Gil</surname><given-names>J.</given-names></name></person-group><article-title>A complex secretory program orchestrated by the inflammasome controls paracrine senescence</article-title><source>Nat. Cell Biol.</source><volume>15</volume><issue>8</issue><year>2013</year><fpage>978</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">23770676</pub-id>
</element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Mogilenko</surname><given-names>D.A.</given-names></name><name><surname>Shchukina</surname><given-names>I.</given-names></name><name><surname>Artyomov</surname><given-names>M.N.</given-names></name></person-group><article-title>Immune ageing at single-cell resolution</article-title><source>Nat. Rev. Immunol.</source><volume>22</volume><issue>8</issue><year>2022</year><fpage>484</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">34815556</pub-id>
</element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>N.</given-names></name><name><surname>Kisslinger</surname><given-names>A.</given-names></name><name><surname>Paladino</surname><given-names>S.</given-names></name><name><surname>Procaccini</surname><given-names>C.</given-names></name><name><surname>Matarese</surname><given-names>G.</given-names></name><name><surname>Pierantoni</surname><given-names>G.M.</given-names></name><name><surname>Mancini</surname><given-names>F.P.</given-names></name><name><surname>Tramontano</surname><given-names>D.</given-names></name></person-group><article-title>Resveratrol couples apoptosis with autophagy in UVB-irradiated HaCaT cells</article-title><source>PLoS One</source><volume>8</volume><issue>11</issue><year>2013</year><object-id pub-id-type="publisher-id">e80728</object-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R.</given-names></name><name><surname>Tardivel</surname><given-names>A.</given-names></name><name><surname>Thorens</surname><given-names>B.</given-names></name><name><surname>Choi</surname><given-names>I.</given-names></name><name><surname>Tschopp</surname><given-names>J.</given-names></name></person-group><article-title>Thioredoxin-interacting protein links oxidative stress to inflammasome activation</article-title><source>Nat. Immunol.</source><volume>11</volume><issue>2</issue><year>2010</year><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">20023662</pub-id>
</element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>Scialo</surname><given-names>F.</given-names></name><name><surname>Sriram</surname><given-names>A.</given-names></name><name><surname>Fernandez-Ayala</surname><given-names>D.</given-names></name><name><surname>Gubina</surname><given-names>N.</given-names></name><name><surname>Lohmus</surname><given-names>M.</given-names></name><name><surname>Nelson</surname><given-names>G.</given-names></name><name><surname>Logan</surname><given-names>A.</given-names></name><name><surname>Cooper</surname><given-names>H.M.</given-names></name><name><surname>Navas</surname><given-names>P.</given-names></name><name><surname>Enriquez</surname><given-names>J.A.</given-names></name><name><surname>Murphy</surname><given-names>M.P.</given-names></name><name><surname>Sanz</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial ROS produced via reverse electron transport extend animal lifespan</article-title><source>Cell Metabol.</source><volume>23</volume><issue>4</issue><year>2016</year><fpage>725</fpage><lpage>734</lpage></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>V.</given-names></name><name><surname>Santoro</surname><given-names>A.</given-names></name><name><surname>Monti</surname><given-names>D.</given-names></name><name><surname>Crupi</surname><given-names>R.</given-names></name><name><surname>Di Paola</surname><given-names>R.</given-names></name><name><surname>Latteri</surname><given-names>S.</given-names></name><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name><name><surname>Zappia</surname><given-names>M.</given-names></name><name><surname>Giordano</surname><given-names>J.</given-names></name><name><surname>Calabrese</surname><given-names>E.J.</given-names></name><name><surname>Franceschi</surname><given-names>C.</given-names></name></person-group><article-title>Aging and Parkinson's Disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis</article-title><source>Free Radic. Biol. Med.</source><volume>115</volume><year>2018</year><fpage>80</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">29080843</pub-id>
</element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Du</surname><given-names>R.H.</given-names></name><name><surname>Qiao</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>C.Y.</given-names></name><name><surname>Zhang</surname><given-names>K.Z.</given-names></name><name><surname>Ding</surname><given-names>J.H.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name></person-group><article-title>MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease</article-title><source>Mol. Neurodegener.</source><volume>11</volume><year>2016</year><fpage>28</fpage><pub-id pub-id-type="pmid">27084336</pub-id>
</element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name><surname>Mejias</surname><given-names>N.H.</given-names></name><name><surname>Martinez</surname><given-names>C.C.</given-names></name><name><surname>Stephens</surname><given-names>M.E.</given-names></name><name><surname>de Rivero Vaccari</surname><given-names>J.P.</given-names></name></person-group><article-title>Contribution of the inflammasome to inflammaging</article-title><source>J. Inflamm.</source><volume>15</volume><year>2018</year><fpage>23</fpage></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name><surname>Youm</surname><given-names>Y.H.</given-names></name><name><surname>Grant</surname><given-names>R.W.</given-names></name><name><surname>McCabe</surname><given-names>L.R.</given-names></name><name><surname>Albarado</surname><given-names>D.C.</given-names></name><name><surname>Nguyen</surname><given-names>K.Y.</given-names></name><name><surname>Ravussin</surname><given-names>A.</given-names></name><name><surname>Pistell</surname><given-names>P.</given-names></name><name><surname>Newman</surname><given-names>S.</given-names></name><name><surname>Carter</surname><given-names>R.</given-names></name><name><surname>Laque</surname><given-names>A.</given-names></name><name><surname>Munzberg</surname><given-names>H.</given-names></name><name><surname>Rosen</surname><given-names>C.J.</given-names></name><name><surname>Ingram</surname><given-names>D.K.</given-names></name><name><surname>Salbaum</surname><given-names>J.M.</given-names></name><name><surname>Dixit</surname><given-names>V.D.</given-names></name></person-group><article-title>Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging</article-title><source>Cell Metabol.</source><volume>18</volume><issue>4</issue><year>2013</year><fpage>519</fpage><lpage>532</lpage></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>A.</given-names></name><name><surname>Gottfried-Blackmore</surname><given-names>A.C.</given-names></name><name><surname>McEwen</surname><given-names>B.S.</given-names></name><name><surname>Bulloch</surname><given-names>K.</given-names></name></person-group><article-title>Microglia derived from aging mice exhibit an altered inflammatory profile</article-title><source>Glia</source><volume>55</volume><issue>4</issue><year>2007</year><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">17203473</pub-id>
</element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>D.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Lartigue</surname><given-names>L.</given-names></name><name><surname>Bolen</surname><given-names>C.R.</given-names></name><name><surname>Haddad</surname><given-names>F.</given-names></name><name><surname>Gaudilliere</surname><given-names>B.</given-names></name><name><surname>Ganio</surname><given-names>E.A.</given-names></name><name><surname>Fragiadakis</surname><given-names>G.K.</given-names></name><name><surname>Spitzer</surname><given-names>M.H.</given-names></name><name><surname>Douchet</surname><given-names>I.</given-names></name><name><surname>Daburon</surname><given-names>S.</given-names></name><name><surname>Moreau</surname><given-names>J.F.</given-names></name><name><surname>Nolan</surname><given-names>G.P.</given-names></name><name><surname>Blanco</surname><given-names>P.</given-names></name><name><surname>Dechanet-Merville</surname><given-names>J.</given-names></name><name><surname>Dekker</surname><given-names>C.L.</given-names></name><name><surname>Jojic</surname><given-names>V.</given-names></name><name><surname>Kuo</surname><given-names>C.J.</given-names></name><name><surname>Davis</surname><given-names>M.M.</given-names></name><name><surname>Faustin</surname><given-names>B.</given-names></name></person-group><article-title>Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states</article-title><source>Nat. Med.</source><volume>23</volume><issue>2</issue><year>2017</year><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">28092664</pub-id>
</element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name><surname>Villeda</surname><given-names>S.A.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Mosher</surname><given-names>K.I.</given-names></name><name><surname>Zou</surname><given-names>B.</given-names></name><name><surname>Britschgi</surname><given-names>M.</given-names></name><name><surname>Bieri</surname><given-names>G.</given-names></name><name><surname>Stan</surname><given-names>T.M.</given-names></name><name><surname>Fainberg</surname><given-names>N.</given-names></name><name><surname>Ding</surname><given-names>Z.</given-names></name><name><surname>Eggel</surname><given-names>A.</given-names></name><name><surname>Lucin</surname><given-names>K.M.</given-names></name><name><surname>Czirr</surname><given-names>E.</given-names></name><name><surname>Park</surname><given-names>J.S.</given-names></name><name><surname>Couillard-Despres</surname><given-names>S.</given-names></name><name><surname>Aigner</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Peskind</surname><given-names>E.R.</given-names></name><name><surname>Kaye</surname><given-names>J.A.</given-names></name><name><surname>Quinn</surname><given-names>J.F.</given-names></name><name><surname>Galasko</surname><given-names>D.R.</given-names></name><name><surname>Xie</surname><given-names>X.S.</given-names></name><name><surname>Rando</surname><given-names>T.A.</given-names></name><name><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>The ageing systemic milieu negatively regulates neurogenesis and cognitive function</article-title><source>Nature</source><volume>477</volume><issue>7362</issue><year>2011</year><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">21886162</pub-id>
</element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name><surname>Villeda</surname><given-names>S.A.</given-names></name><name><surname>Plambeck</surname><given-names>K.E.</given-names></name><name><surname>Middeldorp</surname><given-names>J.</given-names></name><name><surname>Castellano</surname><given-names>J.M.</given-names></name><name><surname>Mosher</surname><given-names>K.I.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>L.K.</given-names></name><name><surname>Bieri</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Berdnik</surname><given-names>D.</given-names></name><name><surname>Wabl</surname><given-names>R.</given-names></name><name><surname>Udeochu</surname><given-names>J.</given-names></name><name><surname>Wheatley</surname><given-names>E.G.</given-names></name><name><surname>Zou</surname><given-names>B.</given-names></name><name><surname>Simmons</surname><given-names>D.A.</given-names></name><name><surname>Xie</surname><given-names>X.S.</given-names></name><name><surname>Longo</surname><given-names>F.M.</given-names></name><name><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice</article-title><source>Nat. Med.</source><volume>20</volume><issue>6</issue><year>2014</year><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">24793238</pub-id>
</element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name><surname>Pissadaki</surname><given-names>E.K.</given-names></name><name><surname>Bolam</surname><given-names>J.P.</given-names></name></person-group><article-title>The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease</article-title><source>Front. Comput. Neurosci.</source><volume>7</volume><year>2013</year><fpage>13</fpage><pub-id pub-id-type="pmid">23515615</pub-id>
</element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name><surname>Bliederhaeuser</surname><given-names>C.</given-names></name><name><surname>Grozdanov</surname><given-names>V.</given-names></name><name><surname>Speidel</surname><given-names>A.</given-names></name><name><surname>Zondler</surname><given-names>L.</given-names></name><name><surname>Ruf</surname><given-names>W.P.</given-names></name><name><surname>Bayer</surname><given-names>H.</given-names></name><name><surname>Kiechle</surname><given-names>M.</given-names></name><name><surname>Feiler</surname><given-names>M.S.</given-names></name><name><surname>Freischmidt</surname><given-names>A.</given-names></name><name><surname>Brenner</surname><given-names>D.</given-names></name><name><surname>Witting</surname><given-names>A.</given-names></name><name><surname>Hengerer</surname><given-names>B.</given-names></name><name><surname>Fandrich</surname><given-names>M.</given-names></name><name><surname>Ludolph</surname><given-names>A.C.</given-names></name><name><surname>Weishaupt</surname><given-names>J.H.</given-names></name><name><surname>Gillardon</surname><given-names>F.</given-names></name><name><surname>Danzer</surname><given-names>K.M.</given-names></name></person-group><article-title>Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes</article-title><source>Acta Neuropathol.</source><volume>131</volume><issue>3</issue><year>2016</year><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">26576561</pub-id>
</element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>R.</given-names></name><name><surname>Albornoz</surname><given-names>E.A.</given-names></name><name><surname>Christie</surname><given-names>D.C.</given-names></name><name><surname>Langley</surname><given-names>M.R.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Mantovani</surname><given-names>S.</given-names></name><name><surname>Robertson</surname><given-names>A.A.B.</given-names></name><name><surname>Butler</surname><given-names>M.S.</given-names></name><name><surname>Rowe</surname><given-names>D.B.</given-names></name><name><surname>O'Neill</surname><given-names>L.A.</given-names></name><name><surname>Kanthasamy</surname><given-names>A.G.</given-names></name><name><surname>Schroder</surname><given-names>K.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name><name><surname>Woodruff</surname><given-names>T.M.</given-names></name></person-group><article-title>Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice</article-title><source>Sci. Transl. Med.</source><volume>10</volume><issue>465</issue><year>2018</year></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Z.</given-names></name><name><surname>Krasnoslobodtsev</surname><given-names>A.V.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ysselstein</surname><given-names>D.</given-names></name><name><surname>Rochet</surname><given-names>J.C.</given-names></name><name><surname>Blanchard</surname><given-names>S.C.</given-names></name><name><surname>Lyubchenko</surname><given-names>Y.L.</given-names></name></person-group><article-title>Effect of acidic pH on the stability of alpha-synuclein dimers</article-title><source>Biopolymers</source><volume>105</volume><issue>10</issue><year>2016</year><fpage>715</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">27177831</pub-id>
</element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Won</surname><given-names>S.J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fong</surname><given-names>R.</given-names></name><name><surname>Butler</surname><given-names>N.J.M.</given-names></name><name><surname>Moss</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Sanchez</surname><given-names>J.</given-names></name><name><surname>Huynh</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Manfredsson</surname><given-names>F.P.</given-names></name><name><surname>Swanson</surname><given-names>R.A.</given-names></name></person-group><article-title>alpha-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism</article-title><source>Prog. Neurobiol.</source><volume>202</volume><year>2021</year><object-id pub-id-type="publisher-id">102070</object-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Shao</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Hypoxic stress accelerates the propagation of pathological alpha-synuclein and degeneration of dopaminergic neurons</article-title><source>CNS Neurosci. Ther.</source><volume>29</volume><issue>2</issue><year>2023</year><fpage>544</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">36514210</pub-id>
</element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Ahn</surname><given-names>E.H.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Kang</surname><given-names>S.S.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>M.H.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>K.</given-names></name></person-group><article-title>C/EBPbeta/AEP is age-dependently activated in Parkinson's disease and mediates alpha-synuclein in the gut and brain</article-title><source>NPJ Parkinsons Dis</source><volume>9</volume><issue>1</issue><year>2023</year><fpage>1</fpage><pub-id pub-id-type="pmid">36609384</pub-id>
</element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name><surname>Won</surname><given-names>S.J.</given-names></name><name><surname>Fong</surname><given-names>R.</given-names></name><name><surname>Butler</surname><given-names>N.</given-names></name><name><surname>Sanchez</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name><name><surname>Tambou Nzoutchoum</surname><given-names>O.</given-names></name><name><surname>Huynh</surname><given-names>A.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Swanson</surname><given-names>R.A.</given-names></name></person-group><article-title>Neuronal oxidative stress promotes alpha-synuclein aggregation in vivo</article-title><source>Antioxidants</source><volume>11</volume><issue>12</issue><year>2022</year></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>X.</given-names></name><name><surname>Tao</surname><given-names>E.</given-names></name></person-group><article-title>Alpha-synuclein induces neuroinflammation injury through the il6st-AS/STAT3/HIF-1alpha Axis</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume><issue>2</issue><year>2023</year></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>P.J.</given-names></name><name><surname>Timothy Greenamyre</surname><given-names>J.</given-names></name></person-group><article-title>Post-translational modification of alpha-synuclein in Parkinson's disease</article-title><source>Brain Res.</source><volume>1628</volume><issue>Pt B</issue><year>2015</year><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">26080075</pub-id>
</element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name><surname>von Herrmann</surname><given-names>K.M.</given-names></name><name><surname>Salas</surname><given-names>L.A.</given-names></name><name><surname>Martinez</surname><given-names>E.M.</given-names></name><name><surname>Young</surname><given-names>A.L.</given-names></name><name><surname>Howard</surname><given-names>J.M.</given-names></name><name><surname>Feldman</surname><given-names>M.S.</given-names></name><name><surname>Christensen</surname><given-names>B.C.</given-names></name><name><surname>Wilkins</surname><given-names>O.M.</given-names></name><name><surname>Lee</surname><given-names>S.L.</given-names></name><name><surname>Hickey</surname><given-names>W.F.</given-names></name><name><surname>Havrda</surname><given-names>M.C.</given-names></name></person-group><article-title>NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease</article-title><source>NPJ Parkinsons Dis</source><volume>4</volume><year>2018</year><fpage>24</fpage><pub-id pub-id-type="pmid">30131971</pub-id>
</element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>T.K.</given-names></name></person-group><article-title>Does drinking coffee reduce the incidence of Parkinson's disease?</article-title><source>Cureus</source><volume>15</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">e34296</object-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name><surname>Galet</surname><given-names>B.</given-names></name><name><surname>Cheval</surname><given-names>H.</given-names></name><name><surname>Ravassard</surname><given-names>P.</given-names></name></person-group><article-title>Patient-derived midbrain organoids to explore the molecular basis of Parkinson's disease</article-title><source>Front. Neurol.</source><volume>11</volume><year>2020</year><fpage>1005</fpage><pub-id pub-id-type="pmid">33013664</pub-id>
</element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>S.</given-names></name><name><surname>Sekiya</surname><given-names>H.</given-names></name><name><surname>Kondru</surname><given-names>N.</given-names></name><name><surname>Ross</surname><given-names>O.A.</given-names></name><name><surname>Dickson</surname><given-names>D.W.</given-names></name></person-group><article-title>Neuropathology and molecular diagnosis of Synucleinopathies</article-title><source>Mol. Neurodegener.</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>83</fpage><pub-id pub-id-type="pmid">34922583</pub-id>
</element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>B.</given-names></name><name><surname>Sambo</surname><given-names>D.</given-names></name><name><surname>Khoshbouei</surname><given-names>H.</given-names></name></person-group><article-title>Alpha-synuclein modulates dopamine neurotransmission</article-title><source>J. Chem. Neuroanat.</source><volume>83&#x02013;84</volume><year>2017</year><fpage>41</fpage><lpage>49</lpage></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0205">The authors would like to thank Dr. Pamela Wearsch for her feedback in sections of this manuscript.</p></ack></back></article>